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ABSTRACT 
LEANNA R. GENTRY: Targeting the Ras-Ral effector pathway for cancer treatment 
(Under the direction of Channing J. Der) 
 
 The RAS oncogene is the most frequently mutated gene in human cancers, and this activated 
Ras oncoprotein has been shown to be required for both cancer initiation and maintenance. Great 
strides have been made in understanding Ras signaling in cancer since the discovery of its 
involvement in human cancers in 1982, with numerous Ras effector pathways and modes of Ras 
regulation having been identified as contributing to Ras-driven oncogenesis. However, there has been 
limited success in developing strategies for therapeutically targeting Ras-driven oncogenesis. One 
effort that has gained popularity in recent years is the inhibition of Ras effector signaling. The Ral 
(Ras-like) small GTPases, discovered shortly after Ras in an attempt to identify RAS-related genes, 
are activated downstream of Ras by Ral guanine nucleotide exchange factors (RalGEFs). The Ral 
family members have since emerged as critical regulators of key cellular processes and, importantly, 
have been characterized as playing a role in tumorigenesis and invasion of multiple cancer types. 
Interestingly, divergent roles for RalA and RalB are often observed in within a cancer. Due to the 
high affinity of Ral for GTP, which activates Ral upon binding, the Ral GTPase family cannot be 
targeted directly. Therefore, indirect inhibition of Ral must be considered for targeting Ral-dependent 
phenotypes in Ras-driven cancers. This could be achieved through inhibition of Ral association with 
the plasma membrane, which is thought to be required for its activation and subsequent signaling. 
Alternatively, downstream effectors of Ral with validated roles in cancer could be inhibited. 
 Posttranslational processing of the CAAX motif located on the C-termini of Ral GTPases, 
among other proteins, has been considered essential for their proper subcellular localization, 
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activation, and function. The first and essential step of this process is prenylation by GGTase. 
Prenylation signals for further CAAX processing by the enzymes RCE1 and ICMT, which are under 
consideration as therapeutic targets. We determined that the modifications regulated by these 
enzymes have distinct roles and consequences for Ral GTPases. We found that both RalA and RalB 
require RCE1 for association with the plasma membrane, and that the absence of RCE1 caused a 
sustained activation of both RalA and RalB. In contrast, ICMT deficiency disrupted plasma 
membrane localization of RalB but not RalA, whereas RalA depended on ICMT for efficient 
localization to recycling endosomes. Furthermore, ICMT deficiency caused increased stability of 
RalB protein but not RalA. Lastly, we found that palmitoylation was critical for proper subcellular 
localization of RalB but not RalA. In summary, we identified isoform-specific consequences of 
CAAX modifications that could be contributing to the divergent localization and activities of the Ral 
proteins. 
 In order to address inhibiting Ral effectors, we sought to determine the effect of inhibiting 
TBK1, a kinase that is a validated effector of RalB, in pancreatic ductal adenocarcinoma, a disease 
characterized by greater than 90% of cases containing a K-Ras mutation. We found that a novel small 
molecule inhibitor of TBK1, while effective at inhibiting signaling, had a minimal effect on 
pancreatic cancer cell proliferation in vitro and in vivo. However, when combined with inhibition of 
ERK1/2, we found a synergistic proliferation defect and induction of apoptosis. This suggests 
combination approaches with TBK1 inhibitors may provide therapeutic benefit in the treatment of K-
Ras-driven pancreatic cancer. Overall, this work provides further insight into strategies for targeting 
Ral for the treatment of cancer. 
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Chapter 1: Introduction
1
 
 
Ral GTPase family. Identified initially as Ras-like (Ral) proteins, the Ral small GTPases are members 
of the Ras branch of the Ras superfamily of small GTPases [1]. RALA was identified initially using 
oligonucleotide probes to identify RAS-related genes in a cDNA library established from immortalized 
simian B-lymphocytes [2]. Three years later, using the simian RALA cDNA as a probe, human RALA and 
a related RALB gene were identified from a human pheochromocytoma cDNA library [3].  Subsequently, 
single RAL orthologs were identified in C. elegans (RAL-1) [4] and Drosophila (RalA) [5] (Fig. 1-1). 
Interestingly, although there are well-conserved RAS orthologs in yeast, no RAL orthologs are present in S. 
cerevisiae or S. pombe.   
The three human RAS genes (HRAS, KRAS and NRAS) comprise one of the most frequently 
mutated gene families in human cancers [6]. Consequently, they have been the subject of intense research 
scrutiny and cancer drug discovery. Initially, the discovery of Ral proteins simply added to a rapidly 
growing roster of proteins that now comprise a large superfamily of >150 Ras-related small GTPases [1]. 
However, with discoveries that Ral GTPases are key regulators of vesicular trafficking and are effectors 
of Ras oncoprotein-driven growth transformation, Ral proteins stepped into the spotlight in 2003 to bask 
in their “15 minutes of fame” [7]. Since those initial findings, more discoveries on the role of Ral in 
normal and cancer cell physiology have ensured that their “fame” will last considerably more than 15 
                                                     
1
 This chapter is adapted from a previously published work: Gentry LR, Martin TD, Reiner DJ, Der CJ. “Ral small 
GTPase signaling and oncogenesis: More than just 15 minutes of fame.” Biochim Biophys Acta 2014 1843 (12) 
2976-2988 
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minutes. In this review, we summarize our current knowledge on Ral GTPases and we highlight recent 
findings in Ral function. 
Ral protein structure. The highly related human RalA and RalB isoforms share 82% overall amino acid 
sequence identity (Fig. 1-1A) and are members of the Ras branch of the Ras superfamily (Fig. 1-1B). 
They share 46-51% sequence identity and domain architecture with Ras proteins  [8]. However, Ral 
proteins contain an N-terminal 11 amino acid extension not found in Ras, accounting for the 11 residue 
shift in numbering compared with Ras residue numbering (Fig. 1-1C). This is followed by the G domain, 
involved in GTP binding and hydrolysis, and the C-terminal membrane targeting sequence. The majority 
of sequence divergence occurs within the C-terminal hypervariable regions (50% shared identity) (Fig. 1-
1C).  
Like Ras, Ral proteins cycle between inactive GDP-bound and active GTP-bound states (Fig. 1-
2A).  RalA and RalB share complete sequence identity in the switch I (SI) and II (SII) sequences that 
change conformation during GDP-GTP cycling [8] (Fig. 1-2B).  As described below, SI and SII are 
involved in recognition by both regulators and effectors.  The conservation of SI and SII sequences in 
Drosophila and C. elegans Ral proteins support their interaction with conserved regulators and effectors. 
Similar to Ras, the intrinsic GDP-GTP exchange and GTP hydrolysis activities of Ral GTPases 
are very weak, with each activity accelerated by Ral-selective guanine nucleotide exchange factors 
(RalGEFs) and GTPase activating proteins (RalGAPs), respectively (Fig. 1-2A).  RalGEFs stimulate 
guanine nucleotide exchange. With intracellular levels of GTP approximately 10-fold higher than GDP, 
RalGEF stimulation favors formation of Ral-GTP. Ral GTPase-activating proteins (RalGAPs) catalyze 
the hydrolysis of the bound GTP, returning Ral to an inactive conformation.  When bound to GTP, RalA 
and RalB can interact with the same array of downstream effector proteins and mediate numerous cellular 
processes. 
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Figure 1-1. Evolutionary conservation of Ral small GTPases. A. Human and invertebrate Ral orthologs exhibit 
strong sequence identity. The RalA and RalB isoforms are found in all vertebrate species. There is one Ral ortholog 
in C. elegans (Ce) and D. melanogaster (Dm). Overall sequence identity was determined by CLUSTALW multiple 
sequence alignment. B. Ral GTPases are members of the Ras branch of the Ras superfamily. Shown here is a 
comparison with the four Ras proteins and representative members of the Ras family. The dendrogram was 
generated by CLUSTALW multiple sequence alignment. C. Dendrogram showing sequence relationship of human 
and invertebrate Ral proteins. D. Ral domain structure. Human RalA and RalB G domains (12–176) shares 88% 
sequence identity and contain the SI and SII domains that change in conformation during GDP–GTP cycling and are 
involved in interaction with regulators and effectors. The switch regions are conserved between human Ral proteins 
and Drosophila Ral and differ by a single residue in each switch in C. elegans Ral (identical residues indicated in 
blue text). The hypervariable (HV) C-terminus (50% identity) consists of the membrane targeting region and 
contains key post-translational phosphorylation sites that regulate Ral subcellular localization and effector 
interaction. Multiple sequence alignment was done by ClustalW analyses and domain topology by SMART analyses. 
Numbers correspond to the human Ral amino acid sequences 
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Figure 1-2, A and B. Regulators of the Ral GDP-GTP cycle. A. Regulation of Ral GDP-GTP cycling. Ral-
selective GEFs and GAPs accelerate the low intrinsic exchange and GTP hydrolysis activities to promote formation 
of active GTP-bound and inactive GDP-bound Ral. B. The RalGEFs are highly conserved across species. All 
RalGEFs contain a CDC25 homology domain, which is responsible for catalytic activity. There are four human 
isoforms of RalGEF that contain Ras-association (RA) domain. These isoforms also contain a Ras exchanger motif 
(REM) that likely stabilizes the CDC25 homology domain and is essential for RalGEF catalytic activity. There is 
one homolog in C. elegans and two in Drosophila. The RalGEF homolog in C. elegans is most similar to RalGDS. 
The RalGPS RalGEFs lack a REM domain and do not associate with Ras, but instead contain a pleckstrin homology 
(PH) domain. RGL4 contains a CDC25 homology domain, but lacks a REM, RA or PH domain. 
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Ral GEFs. The first RalGEF identified, Ral guanine nucleotide dissociation stimulator (RalGDS) 
(Fig. 1-2B), was found by yeast two-hybrid screens performed in the early 1990s to identify Ras effectors 
[9-11].  RalGDS was found to catalyze nucleotide exchange on both RalA and RalB but not on other 
small GTPases including members of the Ras, Rho, and Rab families.  Subsequent yeast two-hybrid 
library screening studies using H-Ras, R-Ras, TC21/R-Ras2, and Rit as baits identified three additional 
RalGEF proteins that were named Rgl (RalGDS-like), Rgl2/Rlf, and Rgl3 [12-14] [15].  These RalGEFs 
contain a common domain architecture including an N-terminal Ras exchanger motif (REM) domain 
followed by a CDC25 homology domain (RasGEF) and a C-terminal Ras-association (RA) domain (Fig. 
1-2A)  [16].  The CDC25 homology domain shares sequence identity with the catalytic domains of 
RasGEFs [17]. In addition to the three Ras isoforms, other Ras family small GTPases can also bind and 
activate the RA domain-containing RalGEFs [18]. 
 RalGPS1 and RalGPS2 (Ral GEF with PH domain and SH3-binding motif) comprise a second 
distinct family of RalGEFs [19-21] (Fig. 1-2A).  These two related proteins (63% identity) contain an N-
terminal CDC25 homology RasGEF but lack a REM and RA domain.  Instead, they contain a C-terminal 
pleckstrin homology (PH) domain.  Additionally, they possess is a central proline-rich sequence with 
PxxP motifs recognized by Src homology 3 (SH3) domain-containing proteins. 
The absence of an RA domain uncouples these RalGEFs from direct association with Ras family 
small GTPases.  Instead, the PH domain has been shown to be sufficient for membrane targeting and 
necessary for Ral activation [19].  The regulation of these RalGEFs is poorly understood, but some 
evidence suggests that RalGPS2 plays a role in regulating the actin cytoskeleton [21].  Interestingly, 
members of both RalGEF subclasses have been implicated in cytokinesis [22]. 
 Another RalGEF, now designated RGL4, was identified originally as a RalGDS-related (Rgr) 
oncogene in a DMBA (7,12-dimethylbenz[α]anthracene)-induced rabbit squamous cell carcinoma [23].  
However, while RGL4 does contain a CDC25 homology domain, it lacks a well-defined RA or PH 
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domain (Fig. 1-2B).  Furthermore, while the other RalGEFs described above are highly selective 
activators of Ral, RGR has also been described to activate other Ras family small GTPases [24]. 
RalGAPs. Although the existence of RalGAPs was first reported in 1991 [25], only recently has the 
molecular identification of RalGAPs been achieved (Fig. 1-2C).  Work done by Feig and colleagues in the 
early 1990s detected and characterized RalGAP activity in brain and testes cytosolic extracts, and the 
putative RalGAP activity was distinct in size from Ras or Rho GAPs [25].  Subsequently, using a 
GTPase-deficient, persistently GTP-bound mutant of RalA for affinity chromatography, two distinct 
RalGAP complexes were identified in brain cytosol [26].  Each heterodimeric complex consists of a 
shared regulatory RalGAPβ subunit and one of two related catalytic RalGAPα1 and α2 subunits (53% 
overall sequence identity) (Figs. 1-2A and 1-2C).  Independently, Saltiel and colleagues used a similar 
RalA affinity purification approach and identified RalGAPα2 (RGC2) and RalGAPβ (RGC1) as 
components of a Ral-selective GAP [27]. 
RalGAPα1 (GARNL1/TULIP1) and RalGAPα2 (AS250; Akt substrate of 250 kDa) were 
identified previously as proteins with sequence identity with the GAP catalytic domain of TSC2 (also 
known as tuberin) [28, 29] (Fig. 1-2B) and distinct from the RasGAP catalytic domain [17].  RalGAPα2 
was also identified to form a complex with RalGAPβ (KIAA1219). TSC2 is the catalytic subunit of a 
GAP selective for the Rheb small GTPases, another member of the Ras branch of the Ras superfamily [1]. 
However, TSC2 alone is not sufficient for RhebGAP activity and requires heterodimer formation with 
TSC1 (also known as hamartin). Hence, the active RalGAPα/β complexes share both sequence and 
structural similarities with the heterodimeric tuberous-sclerosis (TSC) complex [30].  Although RalGAPβ 
lacks sequence similarity with Tsc1, it serves an analogous role in stabilizing RalGAPα and is required 
for RalGAP activity.  RalGAPβ is expressed ubiquitously, whereas more variable expression profiles are 
seen for the two RalGAPα subunits.  RalGAPs are conserved in evolution, with orthologs of both subunits 
found in C. elegans and Drosophila (Fig. 1-2B) [26, 31]. The RalGAPα GAP catalytic domains of C. 
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elegans (HGAP-1) and Drosophila (CG5521) share 37-39% and 58-59% sequence identity, respectively, 
with the GAP catalytic domains of their human counterparts. 
RalGAP accelerates the GTPase activity of both RalA and RalB but not for other small GTPases 
tested (H-Ras, Rap1, Rheb, RhoA, Ran and Rab27) [26, 27, 31].  The RalGAPα subunits share 53% 
overall sequence identity and 83% sequence identity in their GAP domains (Figs. 1-2C and 1-2D).  
Additionally, RalGAPα2 is subject to insulin-stimulated phosphorylation by the AKT serine/threonine 
kinase, analogous to a similar mechanism of AKT regulation of TSC2 [32].  As with TSC2, AKT 
phosphorylation of RalGAPα2 impaired the ability of the RalGAP complex to catalyze RalA GTP 
hydrolysis. This is not due to altered intrinsic GAP activity but to a reduced RalA interaction with 
RalGAPα2. 
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Figure 1-2, C and D. Regulators of the Ral GDP-GTP cycle. C. The RalGAPs are heterodimeric complexes 
formed by either a RalGAPα1 or RalGAPα2 catalytic subunit with the regulatory RalGAPβ subunit. The RalGAPβ 
subunit serves to regulate the catalytic activity of the RalGAPα subunits, similar to TSC1 regulation of TSC2. 
Percentages indicate sequence identity with the RalGAPα1 catalytic domain. Orthologs of the human RalGAPα and 
RalGAPβ subunits are present in C. elegans and Drosophila. Multiple sequence alignment and sequence identity 
were determined by ClustalW analyses and domain topology by SMART analyses. 
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Ral effectors. Like Ras and other small GTPases, Ral interacts with a number of effector proteins when 
bound to GTP (Fig. 1-3).  However, unlike with Ras, the Ral binding domains (RBD) lack primary 
sequence identity. The best characterized Ral effectors are RalBP1/RLIP76 and the Sec5 and Exo84 
subunits of the octameric exocyst complex.  The evolutionarily conserved exocyst complex mediates the 
tethering of post-Golgi secretory vesicles to the plasma membrane prior to exocytic fusion [33].  The 
exocyst subunits may also exist as monomers or subcomplexes, and can possess non-exocyst functions.  
Ral interaction with each subunit occurs in distinct subcellular locations, interacting with Sec5 at the 
plasma membrane and with Exo84 with intracellular vesicles [34, 35]. Although RalA and RalB can 
interact with the same set of effectors in vitro, as described below, the distinct biological functions of 
RalA and RalB are mediated by differences in subcellular localization, leading to their interaction with 
distinct subsets of effectors. 
The structures of Ral in complex with the RBDs of these three effectors have been determined.  
Whereas the Sec5 RBD interacts with SI alone [36], Exo84 [37] and RalBP1 [38] RBD interaction 
involves both SI and SII [39].  Consistent with 100% conservation of SI and SII residues, and residues 
involved with effector binding, where studied, RalA and RalB interact with the same set of effectors in 
vitro. 
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Figure 1-3. Ral effectors and effector functions.  Active Ral can bind to a variety of downstream effectors and 
modulate numerous cellular activities. RalBP1 acts as a RhoGAP as well as a scaffold for other proteins that 
regulate endocytosis and other cellular processes. Ral association with Sec5 or Exo84 can regulate exocyst-
dependent and –independent processes.  Other effector processes include regulation of cell cycle progression 
through PLD1-dependent cytokinesis and cytoskeletal changes through filamin A, IP3 signaling through PLCδ1, and 
gene transcription through ZONAB.  Ral activation also stimulates signaling pathways that lead to the activation of 
various transcription factors (TF), stimulating gene expression. 
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RalBP1. The first Ral effector described, RalBP1 (Ral binding protein 1; also called RLIP76 or 
RIP1), was identified in screens for proteins that bound preferentially to activated RalA [40-42]. RalBP1 
orthologs are found in Drosophila and C. elegans. RalBP1 contains a RhoGAP catalytic domain that has 
activity for the Cdc42 and Rac small GTPases, members of the Rho branch of the Ras superfamily [1].  
Cdc42 stimulates filopodia formation whereas Rac stimulates lamellipodia formation. Thus, RalBP1 
provides a link between Ral and modulation of the actin cytoskeleton changes that drive these cellular 
activities [40].   
In additional to its RhoGAP domain, RalBP1 has additional functions (Fig. 1-3).  Two ATP 
binding motifs have been identified in RalBP1 and shown to be important for transport function involving 
glutathione conjugates of electrophilic compounds [43, 44]. This transport function may facilitate the 
cellular export of chemotherapeutic drugs and radiation-induced oxidative damage byproducts [45].  
RalBP1 overexpression has been found in a spectrum of human cancers, and suppression of RalBP1 
expression can impair tumorigenic growth in vivo [46]. However, phenotypes attributed to RalBP1 do not 
necessarily implicate their role in Ral signaling [47].   
RalBP1 also functions as a scaffold and interacts with a spectrum of functionally distinct proteins 
that regulate endocytosis and signal transduction (Fig. 1-3).  The AP2 adaptor complex, a regulator of 
clathrin-mediated endocytosis from the plasma membrane, associates with the N-terminal region of 
RalBP1 [48]. The Eps homology (EH) domain-containing proteins Reps1 and Reps2 (POB1) were 
identified as proteins that interacted with the C-terminus of RalBP1 [49, 50].  These proteins are known to 
be important for receptor tyrosine kinase-regulated endocytosis, with Reps1 interacting with Rab11-FIP2 
and Reps2 binding Epsin and Eps15 [51, 52]. 
Another protein that associates with the RalBP1 C-terminus is cyclin B1 [53]. In turn, the 
RalBP1-bound cyclin B1 complexes with Cdk1, with Cdk1 phosphorylation of Epsin preventing 
endocytosis during mitosis. This activity was shown to be mediated by RalA activation. 
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 RalBP1 has been implicated as a key effector for several Ral-driven processes.  In these studies, 
the typical approach has been the utilization of mutants of Ral that are selectively impaired in effector 
interaction.  The D49N substitution impairs RalBP1 but not Sec5 or Exo84 effector binding, whereas the 
D49E mutation has the opposite consequence [40, 54, 55]. For example, shRNA silencing analyses 
determined that RalB but not RalA was required for invadopodia formation in pancreatic cancer cell lines 
[56]. RalB D49E but not D49N could rescue loss of endogenous RalB and restore invadopodia formation, 
indicating that RalBP1 was a critical effector for this RalB activity. This RalBP1 function was GAP-
independent but abolished by mutation of the ATP binding motifs [56]. 
RalA was shown to utilize RalBP1 to regulate mitochondrial fission at mitosis [57]. Mitochondria 
exist as dynamic interconnected networks that are maintained through a balance of fusion and fission. 
Fission facilitates equal distribution of mitochondria to daughter cells during mitosis. Fission is controlled 
by the GTPase Drp1 on the outer mitochondrial membrane. RalA was found to recruit RalBP1 to 
mitochondria, where RalBP1 acts as a scaffold to facilitate cyclin B/Cdk1 phosphorylation of Drp1 to 
promote mitochondrial fission. Suppression of either RalA or RalBP1 expression caused a loss of 
mitochondrial fission at mitosis. 
Recently, RalBP1 was shown to be necessary and sufficient for RalA-driven mislocalization of 
the cyclin-dependent kinase inhibitor p27 KIP1, leading to inhibition of TGF-β–mediated growth arrest in 
epithelial cells [58].  This function appeared to require an intact RhoGAP domain. 
 
Sec5 and Exo84 subunits of the exocyst. The best-characterized Ral effectors are two components 
of the exocyst complex, Sec5 and Exo84 [54, 55, 59].  The association of Ral with both Sec5 and Exo84 
has been found to be important in exocytosis.  Ral regulates the subcellular localization of the exocyst 
through mediating Sec5-paxillin association and the assembly of the octameric exocyst complex by 
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interacting with Sec5 and Exo84 [55, 60]. Ral interaction with Sec5 may also regulate exocyst-
independent functions. 
Recent evidence suggests that Ral engages exocyst subunits to perform a variety of cellular 
processes independent of their roles in exocytosis.  White and colleagues found that the association of 
RalB with Sec5 is critical in the innate immune response [61].  RalB binding to Sec5 leads to an 
interaction of Sec5 with TBK1, a protein kinase known to regulate NF-B signaling. Intriguingly, TBK1 
has recently been identified in siRNA screens as a synthetic lethal partner of activated K-Ras [62], 
although a subsequent study failed to support this relationship [63].  Recently, a mechanism where the 
integrin αvβ3 recruited a K-Ras-RalB complex to the plasma membrane to activate TBK1 and NF-B 
signaling was identified (Fig. 1-3) [64]. This signaling mechanism regulated tumor initiation and growth. 
Chapter 3 contains a study of TBK1 inhibition in Ras-driven pancreatic ductal adenocarcinoma (PDAC). 
The association of RalB with the exocyst has also been shown to regulate macroautophagy [34].  
When cells are grown in nutrient-rich conditions, RalB engages Sec5.  Upon nutrient starvation, RalB 
then engages Exo84 and the exocyst, leading to an upregulation of autophagosome formation.  This 
process is mediated through the assembly of the ULK1 serine/threonine kinase and Beclin1-VPS34 
complexes on the exocyst. Autophagy has emerged as a key component of Ras-driven transformation in a 
variety of cell types, perhaps highlighting an underlying importance of Ras-RalGEF signaling in tumor 
cell autophagy. 
Other effectors.  One lesser-characterized Ral effector is phospholipase D1 (PLD1) [65, 66].  
However, unlike other effectors, the association with Ral is not GTP-dependent and instead the 
association is with the N-terminal 11 amino acid extension (Fig. 1-1D). PLD1 is best known for its role in 
converting phosphotidylcholine to phosphatidic acid and choline in response to G-protein coupled 
receptor (GPCR) stimulation.  Recent evidence shows that RalA is necessary for the PLD1-mediated 
stimulation of mTORC1 signaling [67]. Furthermore, the RalA-PLD1 interaction has been shown to 
 26 
 
promote proper p27 localization, thus allowing for proper TGF-β signaling [58]. The interaction of both 
RalA and RalB with PLD1 has been shown to be critical for HeLa cell cytokinesis [22].   
Filamin is an important component of the actin cytoskeleton and is involved in actin crosslinking 
and lamellipodia formation.  The association of RalA with filamin was found to be important for filopodia 
formation in Swiss-3T3 cells [68].  Additionally, RalA did not induce filopodia in a human melanoma 
cell line that lacks expression of filamin. 
Lastly, active RalA has been shown to engage the transcription factor ZONAB (zonula occludens 
1-associated nucleic acid binding protein) in a cell density dependent manner in MDCK cells [69].  At 
high cell densities, RalA engages ZONAB, unlocking the transcription of ZONAB targets, but it is 
unclear which genes are turned on [69].  While a direct role for Ral association with these lesser-studied 
effectors has not been found in Ral-driven cancers, their important roles in mitosis, motility, and gene 
regulation make them intriguing targets as Ral studies progress. 
Post-translational modification and regulation of Ral function. RalA and RalB exhibit the most 
significant sequence divergence in their C-terminal membrane targeting sequences (50% identity) (Fig. 1-
1C).  This sequence divergence results in their distinct subcellular localization that contributes to the 
functional differences described for RalA and RalB by regulating effector utilization in vivo [56, 70-73].  
Both isoforms can be found at the plasma membrane as well as in endomembranes, with cell type 
differences seen.  In this section we summarize the role of posttranslational modifications that regulate 
Ral subcellular localization. 
Ral CAAX modifications. Like the majority of Ras family small GTPases, RalA and RalB 
terminate in a CAAX (C = cysteine, A = aliphatic amino acid; X = terminal amino acid) tetrapeptide 
motif (Fig. 1-4).  The CAAX motif signals for a series of posttranslational modifications that increase 
hydrophobicity and promote membrane anchoring, where the terminal X residue determines protein 
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prenyltransferase specificity [74]. When X = S, A, Q, and M, the protein is preferentially recognized by 
farnesyltransferase (FTase)-catalyzed addition of a C15 farnesyl isoprenoid lipid; when X = L or I, it 
signals for geranylgeranyltransferase type I (GGTase-I)-catalyzed addition of a C20 geranylgeranyl 
isoprenoid. 
For Ral, the initial step is catalyzed by covalent addition of geranylgeranyl to the cysteine residue 
of the CAAX motif by cytosolic GGTase-I [75]. This is followed by endoproteolytic removal of the AAX 
residues, catalyzed by endoplasmic reticulum-associated Ras converting enzyme 1 (RCE1), and 
subsequent carboxylmethylation of the now terminal prenylated cysteine residue, catalyzed by 
isoprenylcysteine carboxyl methyltransferase (ICMT).  
The CAAX-signaled modifications are critical for both RalA and RalB function.  Mutation of the 
cysteine residue to prevent all CAAX-signaled modifications disrupts Ral membrane association and 
function [75].  Similarly, treatment with a pharmacologic inhibitor of GGTase-I also disrupted Ral 
membrane association and signaling.  Since inhibition of the GGTase-I modification prevents all 
subsequent modifications, the role of the Rce1 and ICMT catalyzed modifications in Ral function remain 
to be addressed. 
Recently, the Ral CAAX motifs were identified as members of a distinct subset of CA1A2X 
motifs where the A1 residue is a second cysteine residue (CCAX).  CCAX motifs can undergo an 
alternative modification pathway (Fig. 1-4). As shown for a Rho family small GTPase (Cdc42), this motif 
can signal for dual lipid modification: prenylation followed by covalent addition of a palmitate fatty acid 
[76]. For Cdc42, after the initial GGTase-I catalyzed prenylation step, a Golgi-associated protein 
acetyltransferase (PAT) catalyzes covalent addition of palmitate to the adjacent cysteine residue rather 
than the conventional modification by Rce1 and ICMT. For Cdc42, this alternative modification 
prevented its recognition by RhoGDI, a protein that masks the prenyl lipid and disrupts membrane 
association, resulting in a cytosolic pool of Cdc42.  Since there is no known RalGDI, the consequences of 
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this palmitate modification on Ral subcellular localization and membrane association, and function, have 
not been determined previously. Chapter 2 explores the consequence of RCE1 and ICMT processing as 
well as palmitoylation of the Ral CAAX motif on Ral localization and function. 
 
Figure 1-4. Regulation of Ral subcellular localization and membrane association. CAAX motif-signaled 
posttranslational modifications. Ral is geranylgeranylated by GGTase-1 on the first cysteine residue of the CAAX 
(RalA: CCIL; RalB: CCLL). By the canonical CAAX processing pathway, Ral is then modified at the endoplasmic 
reticulum (ER) by Ras converting enzyme (Rce1) which cleaves between the two cysteine residues. Isoprenyl 
cysteine carboxyl methyltransferase (ICMT) then catalyzes methylation of the isoprenylated free cysteine residue, 
facilitating recruitment to the plasma membrane.  A second non-canonical pathway has been described by which Ral 
is palmitoylated at the cysteine residue at the A1 position by Golgi-associated protein acetyltransferase (PAT) after 
geranylgeranylation.  Palmitate addition is reversible and depalmitoylation is catalyzed by acylprotein thioesterase 
(APT). Whether this double lipid modified form is associated with a different membrane compartment has not been 
determined. Ral subcellular localization is also regulated by a dynamic and reversible protein kinase (PK)-mediated 
phosphorylation and protein phosphatase (PP)-mediated dephosphorylation cycle.  RalA and RalB possess distinct 
C-terminal phosphorylation sites for different protein kinases (PK).  Phosphorylation causes dissociation from the 
plasma membrane and translocation to specific endomembrane compartments, resulting in a switch in effector (E) 
interaction. 
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Phosphorylation regulation of subcellular localization and effector interaction.  An emerging 
theme in the regulation of small GTPases is reversible post-translational modifications that dynamically 
regulate subcellular localization, thereby influencing effector interaction and biological activity [77].  In 
particular, recent studies have highlighted protein kinase-mediated phosphorylation of small GTPases in 
their C-terminal membrane-targeting regions.  For example, K-Ras4B phosphorylation by protein kinase 
C (PKC) on S181 in its C-terminal membrane targeting sequence altered K-Ras4B subcellular 
localization [78]. Nonphosphorylated K-Ras4B was plasma membrane associated, whereas S181 
phosphorylation K-Ras4B caused translocation to mitochondrial and endoplasmic reticulum (ER) 
membranes.  S181 is positioned within a polybasic amino acid stretch in K-Ras4B that serves as a second 
signal that together with the CAAX modifications promote full plasma membrane association. The 
negative charge caused by phosphorylation reduces the positive charge of the polybasic stretch. The ER-
associated K-Ras4B then associated with inositol trisphosphate receptors (InsP3) on the ER in a Bcl-xL-
dependent fashion, blocking the ability of Bcl-xL to potentiate the InsP3 regulated flux of calcium from 
ER to mitochondria that is required for respiration, inhibition of autophagy, and cell survival [79].  
The Ral proteins are also regulated by similar mechanisms, with distinct protein kinases 
phosphorylating serine residues distinct for the C-termini of RalA and RalB (Fig. 1-4).  Aurora-A kinase 
and protein kinase A (PKA) have been found to phosphorylate RalA on S194 [80, 81] and protein 
phosphatase 2A dephosphorylates RalA at S194 as well as S183 [82]. Counter and colleagues showed 
that phosphorylation of RalA on S194 was critical for RalA to promote the anchorage-independent 
growth in vitro and tumorigenic growth in nude mice of pancreatic ductal adenocarcinoma (PDAC) cell 
lines [71].  This phosphorylation event dramatically altered RalA subcellular localization from the plasma 
membrane to internal membranes, where it had an enhanced interaction with RalBP1.  More recently, 
Aurora-A phosphorylation of RalA has been found to promote RalA translocation to the outer face of 
mitochondria, where it then recruits RalBP1 to stimulate mitochondrial fission [57]. 
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Studies by our lab and others have found that RalB is similarly regulated by PKCα 
phosphorylation of S198 in the C-terminal membrane targeting sequence [72, 81]. In one study, it was 
found that S198 phosphorylation caused RalB translocation from the plasma membrane to endocytic 
vesicles [72].  Associated with this change in subcellular localization was a switch in effector utilization. 
Whereas unphosphorylated RalA preferentially associated with Sec5, S198 phosphorylation caused 
preferential association with RalBP1.  Phosphorylation of RalB S198 was necessary for proper exocytic 
vesicle trafficking and fusion at the plasma membrane, with delivery of surface alpha-5 integrin being 
regulated by dynamic RalB phosphorylation.  Independently, Theodorescu and colleagues found that 
phosphorylation of RalB S198 was critical in regulating the ability of RalB to promote the metastatic 
growth of bladder cancer cells in a nude mouse model [81]. 
Ubiquitination.  In the past few years, regulation of small GTPases by ubiquitination has gained 
recognition [77].  For example, monoubiquitination of K-Ras on K147 reduces GAP sensitivity, thus 
allowing K-Ras to remain active and signaling in the absence of upstream input [83].  Ubiquitination of 
the Ral proteins has also been shown to influence their activity and function.  Regulation of the 
ubiquitination of RalA modulated RalA activity as well as lipid raft exposure [84]. Furthermore, 
ubiquitination of RalB promoted binding to Sec5 to regulate innate immunity, whereas deubiquitination 
allowed for binding to Exo84 and subsequent induction of autophagy [85].   
Divergent roles of Ral in cancer. Since RalGEFs participate in downstream signaling from 
activated Ras proteins, it was initially speculated that Ral protein activation may contribute to Ras-driven 
cellular transformation.  However, when explored initially in NIH 3T3 mouse fibroblasts, a critical and 
significant role for Ral GTPases in Ras-driven cancer seemed unlikely [86, 87].  However, when Counter 
and colleagues explored the role of Ral in Ras-mediated growth transformation of immortalized human 
astrocytes, fibroblast or epithelial cells, a more significant role for Ral GTPases as effectors of Ras in 
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human cancer was observed, suggesting species differences in the effectors that are important in Ras 
oncogene function [88].   
That Ral GTPases serve critical roles in human cancer cell growth gained greater traction when 
White and colleagues found that RalB was critical for tumor but not normal cells for survival, while RalA 
was necessary for the anchorage-independent growth of cancer cells [89].  Importantly, this also marked 
the first time RalA and RalB were found to have non-overlapping functions.  Since these key studies, a 
major theme of Ral proteins is their significant and often divergent roles in numerous cancer types.  In the 
following section we review some of the key findings made with regards to the role of the two Ral 
isoforms as drivers in different human cancers. Since the RA domain-containing RalGEFs can be 
activated by other Ras family small GTPases, as well as by non-Ras mechanisms, and since some 
RalGEFs are regulated by non-Ras mechanisms, an involvement of Ral in cancers where RAS mutations 
are not common is not surprising. 
Bladder carcinoma. Evaluation of a panel of human bladder cancer cell lines found preferentially 
increased levels of activated RalA and RalB in RAS-mutant [90] or invasive cell lines [91]. Using RNAi 
or ectopic expression of activated Ral mutants, Theodorescu and colleagues found that RalA and RalB 
played antagonistic roles in the migratory activity of the KRAS-mutant UM-UC-3 bladder cancer cell line, 
with RalA suppressing and RalB enhancing motility [92].   
Activating RAS mutations occur in a low percentage (~10%) of bladder cancers. Therefore, a Ras-
RalGEF mechanism may be less relevant for Ral activation in this cancer type. Consistent with this 
possibility, a recent study found RalGAP2 expression in normal bladder urothelium, but reduced 
expression associated with advanced clinical stage and poor patient survival [91]. Furthermore, genetic 
depletion of Ralgap2 in mice did not cause any apparent abnormalities but did enhance the invasive 
phenotype of chemically-induced bladder tumors. Thus, loss of RalGAP function may be an important 
mechanism for Ral activation in bladder cancer. 
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Colorectal carcinoma. Oncogenic KRAS and NRAS mutations occur in 45% and 8%, respectively, of 
colorectal cancer (CRC) tumors. Ral signaling has been shown to be a critical regulator of the anchorage-
independent growth properties of CRC tumor cells [93].  Martin et al found that RNAi-mediated 
suppression of RalA resulted in a decrease in soft agar colony growth while loss of RalB had the opposite 
effect, leading to an enhancement of anchorage-independent growth.  They found that RalA and RalB 
modulated this phenotype by utilizing both common and distinct effector proteins.  Using Ral effector 
binding mutants that are selectively uncoupled from Exo84, Sec5, or RalBP1, they showed that RalA 
required Exo84 and RalBP1 binding to promote the anchorage-independent growth of CRC cells.  
Conversely, RalB required Sec5 and RalBP1 to suppress soft agar colony formation.  Intriguingly, loss of 
one Ral isoform was found to increase the activation of the other isoform suggesting compensatory 
crosstalk between RalA and RalB.  What specifically mediates this crosstalk between RalA and RalB is 
unknown, but it could be through either enhanced RalGEF accessibility for the remaining Ral protein or a 
downregulation of RalGAP activity upon single Ral isoform depletion.  Depletion of RalB has also been 
shown to cause apoptosis in colorectal cancer cells [61]. 
Hepatocellular carcinoma. RAS mutations are rare (>2%) in hepatocellular carcinoma (HCC). RalA 
was found to be significantly overactivated in hepatocellular carcinoma (HCC) cells and tissues compared 
to nonmalignant samples. Suppression of RalA expression caused a significant decrease in the viability 
and invasiveness of HCC cells. A role for RalB was not addressed. Finally, in a transgenic mouse model 
for HCC (farnesoid X receptor–deficiency induced) elevated RalA-GTP was detected in the liver tumors 
[94]. 
 Lung adenocarcinoma. KRAS mutations are found in 30% of lung adenocarcinomas and several 
studies have addressed the role of Ral in lung cancer.  In one study, variable levels of RalA-GTP, 
independent of KRAS mutation status, were detected in a panel of lung adenocarcinoma or squamous 
carcinoma cell lines [95].  shRNA suppression of RalA expression in the KRAS mutant A549 lung 
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adenocarcinoma cell line reduced the proliferation and invasion in vitro.  In a second more comprehensive 
study, immunohistochemistry analyses of non-small cell lung cancers (NSCLC), it was found that high 
RalA and RalB protein expression was associated with poor survival. The levels of activated RalA but not 
RalB were higher in KRAS-mutant NSCLC cell lines [96]. Depletion of RALA or RALB or both reduced 
anchorage-dependent and –independent growth for either KRAS mutant and wild type cell lines.  
Depletion of RALA, RALB, or both also impaired the tumorigenic growth of KRAS-mutant NSCLC cells.  
Interesting, very limited analyses in this and another study suggested mutation-selective involvement of 
Ral in NSCLC, where KRAS G12C mutant NSCLC cell lines showed greater activation and/or 
dependence on Ral for growth [97].  
In contrast to human lung tumor cell line studies, RalA and RalB were found to exhibit redundant 
functions when assessed in mouse development and in a Kras G12D-driven mouse model of lung 
adenocarcinoma [73].  Ralb deficient mice were viable with no overt phenotype whereas a Rala 
deficiency caused embryonic lethality that was further exacerbated by a combined Ralb deficiency. 
Neither a Rala nor a Ralb deficiency impaired Kras-driven lung tumor development. However, a 
combined loss of both Rala and Ralb significantly reduced lung tumor development. These results 
suggest redundancy in RalA and RalB function for tumor development. One possible explanation for this 
different conclusion may be that the human lung tumor cell line studies addressed the role of Ral in tumor 
maintenance whereas the mouse study addressed the role of Ral in tumor initiation and progression.  
Malignant peripheral nerve sheath tumors. Loss of the NF1 RasGAP, rather than RAS mutational 
activation, is seen in neurofibromatosis type 1 and malignant peripheral nerve sheath tumors (MPNST) 
[98].  When compared with a nontransformed mouse Schwann cell line, RalA-GTP levels were elevated 
in a panel of MPNST cell lines established from tumors that arose from a NF1- and Tp53-deficient 
genetically-engineered mouse model. When evaluated in one cell line, RalA suppression impaired 
proliferation and invasion in vitro and tumorigenic growth in vivo [99].  RalA activation was also seen in 
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human MPNST cell lines and tissue, and restoration of NF1 GAP activity reduced RalA activity, 
indicating that this was associated with Ras activation. 
Melanoma. RAS mutations, predominantly NRAS, occur in 28% of skin cutaneous melanomas.  With 
BRAF mutations seen in 60% of melanomas in a non-overlapping frequency with RAS mutations, 
activation of the canonical Raf-MEK-ERK mitogen-activated protein kinase (MAPK) pathway alone may 
seem to be sufficient for Ras-driven melanoma growth.  However, analysis of Ral activation in a panel of 
human melanoma cells showed a consistently high level of total and activated RalA, but not RalB, 
activation that was independent of NRAS or BRAF mutation status [100]. Additionally, RalA and to a 
lesser degree RalB are necessary for the tumorigenic growth of melanomas, also regardless of BRAF and 
NRAS mutation status.  
Studies using tumor suppressor Arf-deficient immortalized mouse melanocytes to investigate the 
contributions of Ras downstream signaling to melanomagenesis also indicated a role for Ral signaling 
[101]. Ectopic expression of the RalGEF Rgl2 engineered to contain a membrane localization sequence 
(to mimic Ras activation of RalGEF) was sufficient to promote the anchorage-independent growth and 
Matrigel invasion of these melanocytes similar to that caused by oncogenic N-Ras. Surprisingly, in 
contrast, activated BRAF V600E did not enhance proliferation or invasion.  Finally, ectopic expression of 
a dominant negative mutant of RalB that blocks RalGEF function partially impaired the growth of NRAS-
transformed melanocytes.  Thus, together with the findings of Zipfel et al. [100], Ral GTPases can act as 
drivers of melanoma cancer growth in both RAS wild type and mutant cancer cells. 
 Ovarian carcinoma. One study has now revealed that Ral signaling has a role in ovarian cancer.  
Specifically, higher levels of RalA activity was found in human tumor samples compared to benign 
samples. Furthermore, depletion of RalA decreased proliferation and invasion of ovarian cancer cell line 
OVCAR-5 in vitro and decreased tumor genesis [102]. 
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Pancreatic ductal adenocarcinoma. A significant requirement for activated Ral signaling in 
pancreatic adenocarcinoma (PDAC) cell line tumorigenic and invasive growth has been established.  
Human PDAC has a high frequency or activating KRAS mutations and Ral activation is seen in both 
human tissue samples and tumor cell lines [103-105].  Interestingly, activation of RalA was found at a 
higher frequency than the activation of either ERK or AKT in PDAC cells, suggesting a critical role for 
the RalGEF-Ral pathway downstream of oncogenic K-Ras.   
Depletion of RalA and RalB via RNAi has elucidated roles for RalA in anchorage-independent 
and tumorigenic growth and RalB in invasive and metastatic growth of PDAC cells [105].  PDAC cells 
with stable RNAi depletion of RalA results in reduced subcutaneous tumor formation upon injection into 
immune compromised mice.  These same cells expressing RalB RNAi do not form lung metastases post-
injection into the tail-vein of nude mice.  In addition to playing a role in tumor initiation, RalA has also 
been shown to be necessary for PDAC tumor maintenance.   The use of inducible RNAi to stably deplete 
RalA from established primary tumors resulted in regression of the tumor, indicating a necessity for 
persistent RalA signaling in established PDAC tumors.   
There is also recent evidence that active K-Ras signaling to RalB but not RalA plays a critical 
role in the formation of invadopodia in PDAC cells [56].  Invadopodia are actin-rich membrane 
protrusions that are known to be involved in the secretion of matrix metalloproteases (MMP) during 
tumor cell invasion.  RalB requires the ability to interact with RalBP1 to mediate this process and RalBP1 
itself is necessary for the formation of invadopodia in PDAC cells.  Surprisingly, the RhoGAP activity of 
RalBP1 is not necessary for invadopodia formation while the ATPase activity is required.  Why the 
ATPase activity is necessary for RalBP1 to mediate invadopodia formation is unclear. 
 RalGEFs have also been found to play a role in PDAC.  Rgl2 is overexpressed in PDAC patient 
tumors and has been shown to be necessary for both the anchorage-independent and invasive growth of 
PDAC tumor cells [106].  RNAi-mediated depletion of Rgl2 results in a significant decrease in both RalA 
 36 
 
and RalB activation.  Interestingly, expression of constitutively active RalA could not rescue soft agar 
growth after the loss of Rgl2 indicating that Rgl2 may have non-Ral regulatory functions or that the RalA 
interaction with Rgl2 is critically important for the regulation of anchorage-independent growth.  Rgl2 
was found to be co-localized with RalB but not RalA at the leading edge of migrating CFPac-1 PDAC 
cells.  Loss of Rgl2 results in a loss of RalB from the leading edge, perhaps giving insight into how the 
migratory and invasive activity of PDAC cells relies on Rgl2/RalB signaling. 
Prostate carcinoma. Increased RalA-GTP levels were observed in the RAS wild type human prostate 
carcinoma cell line PC3. Suppression of RalA did not impair tumor formation but did abolish bone 
metastasis [107].  In contrast, suppression of RalB expression did not impair metastasis. 
Squamous cell carcinoma. Squamous cell carcinoma is the second most common type of skin 
cancer. Using an in vitro model of Ras-induced human squamous cell carcinoma (SCC) of the skin, it was 
found that RalA suppressed rather than promoted progression [108].  Suppression of RalA but not RalB 
stimulated the progression of HRAS-transformed human keratinocytes to a more invasive state.   
In contrast to the in vitro observations, different roles for Ral were observed in a mouse model of 
carcinogen-induced SCC [73].  Single application of the mutagen DMBA, followed by repeated 
applications of phorbol ester 12-O-tetradecanoylphorbol 13-acetate (TPA) causes Hras mutation and the 
development of benign papillomas, with a subset progressing to SCC.  Neither a Rala nor a Ralb 
deficiency impaired papilloma development. As described above for Kras-driven lung adenocarcinoma 
formation, only combined loss of both Rala and Ralb significantly reduced papilloma development. 
Genetic ablation of Ralgds in this same carcinogenesis model also significantly reduced tumor incidence, 
size, and progression [109].  
Conclusions and Future Prospects. Ral GTPase signaling has emerged as being critically important 
in both normal and neoplastic cell physiology.  Over the last two and a half decades we have learned a 
great deal about how Ral proteins regulate many biological processes.  From these studies one of the most 
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striking observations has been the very distinct functions observed for RalA and RalB despite similar 
structural and biochemical properties and shared effector utilization.  Do these distinct functions simply 
reflect their spatially distinct interactions with the same set of effectors or are there Ral isoform selective 
effectors that remain to be discovered? Only recently have RalGAPs been discovered and much more 
remains to be learned regarding their roles in regulation of Ral activity and signaling. With increasing 
evidence for key roles for Ral GTPases as drivers in cancer growth, it will be important to identify 
pharmacologic approaches for targeting aberrant Ral function for cancer treatment.  Like Ras, Ral 
proteins are not tractable therapeutic targets, although recent progress in the identification of direct Ras 
binders suggests that small GTPases may yet be targeted directly.  If not, indirect approaches need to be 
explored. With kinases implicated as downstream effectors or key regulators of Ral GTPases, can these 
be exploited for anti-Ral drug development?   In summary, with more yet to be learned regarding the 
function of Ral GTPases, it is quite certain that they will have more than 15 minutes of fame.   
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Chapter 2: Divergent Roles of CAAX Motif-Signaled Posttranslational 
Modifications in the Regulation and Subcellular Localization of Ral GTPases
1
 
 
Background 
 As mentioned in Chapter 1, the Ral proteins, like Ras, contain a C-terminal CAAX motif that 
undergoes prenylation followed by cleavage by RCE1 and carboxylmethylation by ICMT (Fig. 1-4). 
These processing enzymes are being considered as therapeutic targets in the treatment of cancer since 
their activities are thought to be necessary for proper subcellular localization and function of CAAX-
containing proteins. While their usefulness as therapeutic targets is still not fully understood, progress has 
been made in further elucidating the roles of RCE1 and ICMT, which will aid in determining how to 
implement inhibitors against these processing enzymes for the treatment of cancer. 
 RCE1 was initially discovered as a Ras processing protein in S. cerevisiae, where RCE1 
disruption was shown to cause Ras mislocalization and signaling [110]. RCE1 is an integral membrane 
protein of the ER [111]. It is the only enzyme with this particular cleavage activity, and was found to 
cleave most CAAX sequences efficiently with few exceptions [112-114]. Since targeting Ras has long 
been of interest in the field of cancer therapeutics, many studies focused on the role of RCE1 catalytic 
activity in Ras-dependent processes. It has been shown that RCE1 can process all Ras isoforms, and that 
deletion of RCE1 reduced Ras-driven transformation of mouse embryo fibroblasts [115, 116]. Although 
there have been numerous discoveries about RCE1 biology, progress toward RCE1 inhibitors has been
 
1
Adapted from previously published work: Gentry LR, Nishimura A, Cox AD, Martin TD, Tsygankov D, 
Motohiro N, Elston TC, and Der CJ. “Divergent roles of CAAX motif-signaled posttranslational 
modifications in the regulation and subcellular localization of Ral GTPases.” J Biol Chem 2015 290 (37) 
22851-62. All figures except Figure 2-6 D and E represent the work of Leanna R. Gentry. 
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limited. The first documented RCE1 inhibitors were AOMKs ((acyloxy)methyl ketones), which were 
shown to block K-Ras4B cleavage [117, 118]. Another study showed compounds identified in an in vitro 
screen for small molecule inhibitors of RCE1 that disrupted Ras subcellular localization [119, 120]. 
However, these inhibitors lack sufficient potency and selectivity and have not been implemented in 
cancer cell assays.  In the absence of useful pharmacologic inhibitors, the assessment of their roles in 
cancer growth remains unknown and underexplored. Thus, Rce1
-/-
 MEFs remain one of the best options 
for studying the effects of RCE1 loss.
 
 ICMT was initially discovered in S. cerevisiae for its ability to methylate a-factor mating 
pheromone, and it was quickly shown that ICMT methylates Ras as well [121, 122]. ICMT is also 
localized at the ER [123]. One study found that ICMT was required for Ras-driven myeloproliferative 
disease. In contrast, a second study demonstrated its absence resulted in exacerbation of K-Ras-driven 
pancreatic cancer growth.  These opposing observations highlight the fact that our understanding of 
whether ICMT is a useful therapeutic target in Ras-driven cancer remains to be clarified [124, 125]. In 
contrast to RCE1, there has been better progress in developing and characterizing ICMT inhibitors in 
cancer models. Many compounds have been found to inhibit ICMT, including methotrexate and lysine 
nitrilotriacetic acid [126-129]. One such small molecule, cysmethynil, has been shown to decrease both 
anchorage-dependent and –independent growth and cause mislocalization and impaired signaling of Ras 
in colorectal cancer cells [130].  However, this inhibitor has off-target activities that complicate 
interpretation from studies utilizing this inhibitor to assess ICMT as a therapeutic target.  In the absence 
of useful inhibitors, cell models with genetic loss of ICMT function remain the best option.  Icmt
-/-
 MEFs 
have been used widely as the cell system most suited to study the impact of ICMT loss on protein 
function. 
Recently, palmitoylation of the second cysteine of CAAX motifs with the sequence CCAX has 
been reported. This modification was shown to be dependent on prenylation of the first cysteine and 
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results in a dual prenyl and palmitoyl form of the CCAX-containing protein that then does not undergo 
subsequent RCE1- and ICMT-mediated processing steps. Palmitoylation at this site of the brain-specific 
isoform of the Rho family protein Cdc42 was shown to prevent RhoGDIα binding in vitro and promote 
stable Cdc42 membrane association in cells, as opposed to its fully processed form that was instead found 
in the cytosol in addition to membrane fractions [76]. Furthermore, Cdc42 that was alternatively 
palmitoylated displayed greater serum response element (SRE) activity than the canonically processed 
Cdc42, suggesting the palmitoyl from has a greater ability to stimulate downstream signaling. CCAX-
containing RalA, RalB, and PRL-3 were shown to be palmitoylated at this site, and other CCAX-
containing proteins that undergo prenylation may also be subject to palmitoylation of the motif, but the 
consequences of this newly-identified processing pathway on Ral GTPase function has not been studied.  
Unlike Cdc42, Ral GTPases lack a functional counterpart to RhoGDI.  Therefore, the consequences of 
palmitoylation on Ral function are not known. 
 Interestingly, although RCE1 and ICMT expression has been shown to be necessary for certain 
Ras-driven cancers, depletion of either processing enzyme does not fully mislocalize Ras, and it is likely 
that other RCE1- and ICMT-dependent proteins downstream of Ras are at least partially responsible for 
mediating these anti-proliferative effects. It is speculated that there may be as many as 400 mammalian 
CAAX-terminating proteins [131]. Also, while inhibition of palmitoylation is being considered as a 
therapeutic route in Ras driven cancers given recent findings that palmitoylated KRas4A, as well as N-
Ras and H-Ras, are involved in colorectal and other cancers, the consequence of this modification on 
other small GTPases is not understood. In Chapter 2, I explore the effect of RCE1 and ICMT loss as well 
as the consequence of palmitoylation on the function of CCAX-containing Ral proteins. 
Introduction 
The Ras-like (Ral) small GTPases (RalA and RalB) are members of the Ras branch of the Ras 
superfamily of small GTPases [132-134]. Like Ras, Ral small GTPases function as molecular on-off 
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switches and cycle between inactive GDP- and active GTP-bound states.  The cycle is catalyzed by Ral-
selective guanine nucleotide exchange factors (RalGEFs) and GTPase-activating proteins (RalGAPs), 
which accelerate slow intrinsic exchange and GTPase activities, respectively [106].  Ral GTPases are 
activated downstream of Ras oncoproteins. Activated Ras-GTP binds to and activates RalGEFs (e.g., 
RalGDS), stimulating formation of Ral-GTP.  Active Ral-GTP binds preferentially to a spectrum of 
functionally diverse downstream effectors to regulate a diversity of cellular processes that include actin 
cytoskeletal organization, endocytosis and exocytosis, and mitochondrial function [57, 70, 135, 136] as 
well as cell proliferation, survival and autophagy [31, 34]. The best validated effectors of Ral are the Sec5 
and Exo84 subunits of the exocyst complex and RalBP1/RLIP76, a GAP for Rho family small GTPases 
[132-134]. 
RalA and RalB share significant overall sequence, structural, and biochemical identity [134]. Their 
amino-terminal G-domains (amino acids 12-176) involved in GTP binding and hydrolysis, RalGEF and 
RalGAP regulation and effector binding share 88% sequence identity.  Remarkably, despite their 
regulation by shared GEFs and GAPs and interaction with shared effectors in vitro, RalA and RalB 
display divergent biological roles in normal and neoplastic cell growth. RalB was found to be specifically 
required for survival of tumor but not normal cells [89]. In contrast, RalA was dispensable for survival, 
but was required for anchorage-independent proliferation. Differences in Ral isoform function have also 
been observed in various cancer types.  Distinct aspects of cell migration were differentially regulated by 
RalA versus RalB in bladder cancer cells [92]. RalA was essential for tumorigenic growth of pancreatic 
cancer cells, whereas RalB was required for invasive and metastatic growth [105]. In contrast, RalA 
promoted whereas RalB antagonized anchorage-independent growth of colorectal carcinoma cells [93].  
Like Ras, Ral proteins terminate in carboxyl-terminal CAAX tetrapeptide motifs (where C = cysteine, 
A = aliphatic amino acid, and X = terminal amino acid; Ral amino acids 203-206) which signal for a 
series of posttranslational modifications that facilitate intracellular trafficking and translocation to the 
plasma membrane. CAAX-signaled modifications begin with covalent addition of an isoprenoid lipid to 
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the cysteine residue of the CAAX motif [131].  The X residue determines protein prenyltransferase 
specificity [74].  RalA and RalB proteins, both of which terminate in leucine, are modified by addition of 
a geranylgeranyl lipid, catalyzed by cytosolic geranylgeranyltransferase-I (GGTaseI) [75, 137]. 
Subsequent cleavage of the –AAX tripeptide by endoplasmic reticulum-associated Ras converting CAAX 
endopeptidase 1 (RCE1) leaves a lipid-modified terminal cysteine. This cysteine is then methylated by 
endoplasmic reticulum-associated isoprenylcysteine carboxylmethyltransferase (ICMT) [138]. 
The RalA and RalB functional differences identified to date have been attributed to the carboxyl-
terminal sequences immediately adjacent to their CAAX motifs [70, 104]. Termed the hypervariable 
region (HVR; amino acids 177-202), this sequence exhibits the greatest divergence between RalA and 
RalB (44% identity) and confers secondary membrane-targeting specificity.  In particular, the RalA and 
RalB carboxyl termini possess phosphorylation sites recognized by distinct protein kinases, where 
phosphorylation causes translocation from the plasma membrane to endomembranes and a change in 
effector interaction [71, 72, 80-82]. However, posttranslational modifications at other sites may also play 
an important role in Ral isoform functions.  
A recent study of the brain-specific isoform of the Rho family small GTPase Cdc42 concluded that 
proteins terminating in a CA1A2X motif in which the A1 residue is a cysteine (CA1A2X = CCAX) can 
undergo an alternative processing pathway [76]. While a majority of Cdc42 undergoes the conventional 
post-prenyl modification pathway involving RCE1 and ICMT, a subset (5-20%) does not undergo RCE1-
catalyzed removal of the AAX residues, and instead the A1 cysteine is covalently modified by 
palmitoylation. The resulting dually lipid-modified, nonmethylated pool of Cdc42 is no longer regulated 
by RhoGDI, leading to enhanced plasma membrane association. The CAAX motif of RalA is CCIL, and 
that of RalB is CCLL [3], suggesting that, like Cdc42, Ral proteins may also undergo this alternative 
processing. However, unlike Cdc42, the membrane association of RalA and RalB is not regulated by 
RhoGDI. While both RalA and RalB were verified to undergo palmitoylation of the A1 cysteine of their 
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CA1A2X motifs [76], the impact of dual lipid modification of the CAAX motif on Ral subcellular 
localization was not determined.   
Additionally, the contributions of the CAAX-signaled RCE1 and ICMT modifications to RalA and 
RalB subcellular localization and membrane association have not been addressed. We therefore 
determined the consequences of RCE1 or ICMT deficiency on these properties of each Ral isoform. We 
found that both RalA and RalB required RCE1 for efficient plasma membrane targeting, whereas only 
RalB required ICMT for this association. Interestingly, while RalA could still concentrate at the plasma 
membrane in the absence of ICMT, it depended on ICMT for localization to recycling endosomes. We 
also found that RCE1 deficiency increased steady-state activity of both RalA and RalB, whereas ICMT 
deficiency increased steady-state levels of RalB but not RalA. Finally, we determined that CA1AX 
palmitoylation was essential for plasma membrane association of RalB, but not of RalA. Pharmacologic 
inhibitors of RCE1 and ICMT are being considered as anti-Ras therapeutic strategies [139]. Since Ral 
GTPases are key drivers of Ras-dependent cancer growth, it will be critical to understand the complex 
and differential consequences of RCE1 and ICMT inhibition for Ral function. 
 
Experimental Procedures 
Plasmids and Cell Lines – cDNAs encoding green fluorescent protein (GFP)-tagged human RalA was 
described previously [71] and RalB was generated for this study as described for RalA. Site-directed 
mutagenesis was done to generate cysteine-to-serine missense mutants of the A1 cysteine residue of the 
Ral CCI/LL CA1A2X motif, which were then subcloned into pEGFP-C3. The pEGFP-RalA/B chimeric 
construct was provided by Dr. Christopher Counter (Duke University). The RalB/A chimeric cDNA was 
subcloned into pEGFP between the BamH1 and Xba1 sites. The pCDH-mCh lentivirus expression vector 
encoding mCherry-tagged RalA was previously described [72]. All constructs were sequence-verified, 
and cloning details are available upon request.  Mouse embryo fibroblasts (MEFs) deficient in RCE1 
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(Rce1
-/-
) or ICMT (Icmt
-/-
) were provided by Dr. Steven Young (UCLA) and cultured as described 
previously [112, 140].  
Transfection, Transferrin Labeling, and Microscopy – Cells were plated, transfected, and imaged as 
described previously [141]. Lipofectamine Plus was used for DNA transfections. Three h after 
transfection, cells were washed and cultured in phenol-red free Dulbecco’s Modified Eagle’s Medium 
(DMEM) supplemented with 10% fetal calf serum. Cells were labeled with transferrin following the 
manufacturer’s protocol (Life Technologies). Cells were imaged in 35-mm culture dishes containing a 15 
mm coverslip on the bottom made of number 1.5 glass (MatTek). Cells were examined with an inverted 
laser-scanning confocal microscope (Zeiss 710 LSM) using an oil immersion 63X objective with a 1.4 
numerical aperture. Images of GFP expression were captured by scanning with a 488 nm line of a solid-
state laser using a BP 490-555 emission filter. Images of mCh and red fluorescent transferrin probes were 
captured by scanning with a 555 nm solid-state laser with the variable secondary dichroic set to 580 nm. 
Images were processed with ImageJ software, and thresholded Manders coefficients using were 
calculated using the colocalization threshold plugin from the Wright Cell Imaging Facility. 
GST Pulldown Assays – Endogenous activated RalA- and RalB-GTP were assayed as we described 
previously, by pulldown analyses using GST-Sec5-RBD (glutathione S-transferase fusion of the Ral-GTP 
binding domain of Sec5) [104]. After SDS-PAGE and immunoblotting with the RalA- (BD Biosciences) 
or RalB- (Millipore) specific antibodies, the amount of active Ral-GTP was normalized to total Ral 
protein levels in total cellular lysates. Western blot analyses with anti--actin (Sigma Aldrich) or anti-
GAPDH (Sigma Aldrich) were done to verify equivalent loading of total cellular protein. 
Detection of Protein Palmitoylation -  Palmitoylated proteins were purified using acyl-resin assisted 
capture (acyl-RAC). Cells were lysed with RIPA buffer (20 mM Hepes-NaOH pH 7.4, 100 mM NaCl, 3 
mM MgCl2, 1% Triton X-100, 0.5% deoxycholate, and 0.1% SDS) supplemented with protease inhibitor. 
Cleared lysates were incubated in RIPA buffer containing 0.1% methyl methanethiosulfonate (MMTS) at 
42 C for 30 min with rotation. Proteins were precipitated with acetone, and then resuspended in binding 
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buffer (100 mM Hepe-NaCl pH 7.4, 1 mM EDTA, and 1% SDS). Samples were mixed with thiopropyl-
Sepharose in the presence of 250 mM hydroxylamine to cleave thioester linkages. As a negative control, 
the same volume of NaCl was added instead of hydroxylamine. After 3 h rotation at room temperature, 
the resins were washed four times with binding buffer, and samples were eluted in buffer containing 50 
mM Tris-HCl pH 6.8, 50 mM DTT, 10% glycerol, and 1% SDS. After immunoblotting with the RalA- 
and RalB- specific antibodies, the palmitoylation stoichiometry was calculated by a ratio of the precipitate 
intensity to the input intensity. 
Quantification of Fluorescence – The statistics of fluorescence intensity were extracted from images 
of individual cells as a function of the distance from the cell edge. Cell masks (binary images) were 
obtained by thresholding with the MovThresh module of the CellGeo package [142]. Each cell mask was 
then morphologically eroded using the MATLAB function “imerode” with a disk of radius 1 to 50 pixels 
as a structural element. At each step of the morphological erosion, the boundary was traced and the 
intensity of the corresponding boundary pixels was determined from the original image. This allowed the 
mean, median, and standard deviation to be calculated for each cell as function of the distance 1 to 50 
pixels from the cell edge. Finally, the intensity profiles for individual cells were normalized to their peak 
(max) values, and then averaged over all cells in a given genotype. These four processing steps constitute 
a single MATLAB code for batch processing.  
Results 
RalA and RalB show distinct requirements for RCE1- and ICMT-mediated posttranslational 
modifications for their subcellular localization and plasma membrane association - We first addressed 
the importance of RCE1- and ICMT-catalyzed modifications in regulating RalA and RalB subcellular 
localization and membrane association. Since there are currently no potent and selective pharmacologic 
inhibitors of these enzymes, we utilized mouse embryo fibroblasts (MEFs) deficient in expression of 
either RCE1 or ICMT [112, 140]. We transiently transfected wild-type (WT), Rce1
-/-
 or Icmt
-/-
 MEFs with 
expression constructs encoding RalA or RalB, which were amino-terminally tagged with green 
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fluorescent protein (GFP) (Fig. 2-1A). To quantitate changes in Ral plasma membrane association, we 
developed a MATLAB image processing script to analyze fluorescence measurements for localization 
patterns in individual cells (Figs. 2-1B and 2-1C). In particular, we quantified the GFP intensity as a 
function of the distance from the plasma membrane to the nucleus. As described previously [70, 72, 136], 
we found that RalA and RalB each exhibited both plasma membrane and endosome localization in WT 
MEFs (Fig. 2-1A). However, we found that, in Rce1
-/- 
MEFs, both RalA and RalB were mislocalized, 
with diminished plasma membrane association and increased diffuse cytoplasmic accumulation, although 
their endosome localization remained intact (Fig. 2-1A). These results were somewhat unexpected, since 
a previous study suggested that small GTPases modified by the hydrophobic geranylgeranyl lipid attached 
to Ral proteins would not be highly dependent on ICMT- and RCE1-catalyzed modifications for efficient 
plasma membrane association [143]. 
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Figure 2-1. Subcellular localization of Ral family proteins is differentially dependent on RCE1 and ICMT 
processing.  Wild-type (WT), Rce1
-/-
, and Icmt
-/-
 MEFs were transiently transfected with expression vectors 
encoding EGFP-tagged RalA or RalB. A, live cells were visualized using confocal microscopy.  Images shown are 
representative of three independent experiments, each of which examined >40 cells. Images were analyzed using our 
MATLAB image processing script for B, EGFP-RalA distribution and C, EGFP-RalB distribution in WT, Rce1
-/-
, 
and Icmt
-/-
 MEFs. Scale bar, 10 µm. 
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Since RCE1 deficiency also prevents the subsequent ICMT modification, we next determined the 
consequences of ICMT deficiency alone. Although the plasma membrane targeting of both Ral isoforms 
depended similarly on RCE1, surprisingly, we found a differential requirement for ICMT in regulating 
RalA versus RalB plasma membrane targeting. In Icmt
-/-
 MEFs, we observed that RalA remained 
concentrated at the plasma membrane, similar to its localization in WT MEFs. Thus, the significant 
disruption of RalA plasma membrane association in Rce1
-/-
 cells was caused by the absence of AAX 
proteolysis. In striking contrast, RalB association with the plasma membrane was reduced significantly in 
Icmt
-/-
 MEFs, instead showing increased diffuse localization in the cytosol.  Thus, plasma membrane 
association of RalB displays a greater requirement for ICMT compared to that of RalA. 
We next investigated the basis for the different susceptibility of RalA and RalB to ICMT deficiency. 
Although their sequence divergence is greatest in the HVR (44% identity), there is also significant 
sequence divergence in the carboxyl-terminal portion of the G-domain (residues 91-153; 68% identity) 
(Fig. 2-2A). To distinguish between the importance of these two blocks of sequence divergence in ICMT-
dependent Ral localization, we utilized chimeric RalA and RalB proteins that terminate in the reciprocal 
HVR (Fig. 2-2A). RalA/B is comprised of the RalA N-terminus (residues 1-176), which includes RalA 
sequences involved in effector and regulatory protein binding, and the carboxyl-terminal HVR of RalB 
(residues 177-204) involved in membrane targeting. Conversely, RalB/A is comprised of the N-terminus 
of RalB (residues 1-176) followed by the carboxyl-terminal HVR of RalA (residues 177-204). We 
transiently expressed GFP-fusion proteins of RalA, RalB, RalA/B or RalB/A in WT or Icmt
-/-
 MEFs and 
observed their localization patterns. As expected, in WT MEFs the RalA/B and RalB/A chimeric proteins 
retained the predominantly plasma membrane localization patterns of full length RalA and RalB (data not 
shown).  However, in Icmt
-/-
 MEFs, whereas RalB/A retained the strong plasma membrane subcellular 
localization of full length RalA (Figs. 2-2A and 2-2B), the RalA/B chimeric protein exhibited a loss of 
plasma membrane association similar to that seen with full length RalB. We conclude that the distinct 
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consequences of ICMT deficiency seen with RalA and RalB are due to sequence divergence in the HVR 
rather than in the G-domain.  
 
 
 
 
Figure 2-2. Hypervariable domain dictates Ral ICMT dependency. A, Chimeric Ral proteins were constructed 
by a reciprocal switch of the carboxyl-terminal residues 176-206 (red arrow) comprised of the hypervariable domain 
and the CAAX motif. RalA/B is comprised of the RalA G-domain (residues 1-176) followed by RalB residues 177-
206, whereas RalB/A is comprised of the RalB G-domain (residues 1-176) followed by RalA residues 177-206. WT, 
Rce1
-/-
 and Icmt
-/-
 MEF cells were transiently transfected with expression constructs encoding EGFP-tagged Ral 
chimeras RalA/B or RalB/A. B, live cells were visualized by confocal microscopy.  Images shown are representative 
of three independent experiments, each of which examined >40 cells.  C, Images from B were analyzed using our 
MATLAB image processing script. Scale bar, 10 µm. 
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Icmt regulates RalA localization to recycling endosomes - Although ICMT deficiency did not 
noticeably impact RalA plasma membrane targeting, we did observe a decreased level of endomembrane-
associated RalA in Icmt
-/-
 MEFs (Fig. 2-1A). Therefore, we used our MATLAB image processing script 
to quantify the spatial distribution of GFP-RalA. Our analysis revealed a decreased concentration of RalA 
closer to the nucleus in Icmt
-/-
 MEFs.  In contrast, RalB association with internal organelles was not 
impacted significantly by ICMT deficiency (Fig. 2-1B). Thus, RalA and RalB association with 
endomembranes exhibited different requirements for ICMT. 
Since RalA is known to localize to recycling endosomes in various cell types [70, 136], we speculated 
that the RalA endomembrane localization that was disrupted in the absence of ICMT included this 
compartment. To address this possibility, we detected recycling endosomes by live cell microscopy using 
a fluorescent transferrin probe, and measured the colocalization of GFP-RalA with transferrin-loaded 
endosomes. Image analysis revealed a significant decrease in colocalization of RalA with transferrin in 
Icmt
-/-
 MEFs compared to WT MEFs, indicating that RalA localization to recycling endosomes was 
impaired in the absence of ICMT (Figs. 2-3A and 2-3B).  
To further validate this finding, we also measured RalA colocalization with a second marker of 
recycling endosomes, Rab9. For these analyses, we co-transfected expression vectors encoding mCherry-
tagged RalA and GFP-Rab9 into WT or Icmt
-/-
 MEFs. Colocalization analysis again showed a significant 
reduction in localization of RalA to Rab9-containing endosomes in Icmt
-/-
 MEFs (Figs. 2-3C and 2-3D). 
These results demonstrate that loss of ICMT significantly impaired RalA localization to recycling 
endosomes. 
  
 51 
 
 
 
 
 
Figure 2-3. RalA localization on recycling endosomes is impaired by loss of ICMT. A, WT and Icmt
-/-
 MEF cells 
were transiently transfected with an expression construct encoding EGFP-RalA and incubated with pHrodo red 
transferrin conjugate for 30 min before visualization by confocal microscopy. The images were overlapped (Merge) 
to indicate the degree of colocalization on endosomes in WT cells compared with Icmt
-/-
. B, Twenty-five images per 
condition were quantified. Values shown are means of Manders coefficients using thresholds ± S.E., and an 
unpaired t test was used to determine significance (p<0.05). C, WT and Icmt
-/-
 MEF cells were transiently 
transfected with expression constructs encoding EGFP-Rab9 and mCh-RalA. Cells were visualized by confocal 
microscopy. Images were merged as described for panel A, and D, were quantified as described in panel B. Scale bar, 
10 µm. 
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RCE1 regulates Ral activity – Since we previously observed that phosphorylation-mediated 
translocation of RalA or RalB from the plasma membrane to endosomes was associated with an increase 
in active GTP-bound protein [71, 72], we speculated that the altered subcellular localization of RalA and 
RalB seen in RCE1- or ICMT-deficient cells might also be accompanied by altered regulation of their 
GDP-GTP cycle and consequently of their activation state. To address this possibility, we first performed 
pulldown analyses to determine the level of activated, GTP-bound endogenous RalA and RalB in WT, 
Rce1
-/-
 and Icmt
-/-
 MEFs. When normalized to total protein, we found that the steady-state levels of both 
endogenous RalA-GTP and RalB-GTP were elevated strikingly in Rce1
-/-
 MEFs compared to WT MEFs 
(Fig. 2-4A). In contrast, there was limited increase in RalA-GTP and no increase in RalB-GTP levels in 
Icmt
-/- 
MEFs, although RalB protein levels were markedly higher in these cells compared to WT MEFs.   
The elevated activity of the Ral GTPases observed in the absence of RCE1 when compared to WT 
cells suggests differential regulation of the mislocalized Ral proteins by their regulatory RalGAPs or 
RalGEFs. To address this possibility, we evaluated the kinetics of RalA-GTP formation in response to 
external stimuli.  Growth factor-stimulated Ral activation is mediated through transient activation of Ras, 
leading to RalGEF activation and a rapid and transient increase in RalA-GTP [144], with RalGAP activity 
then terminating the activation. A previous study showed that, in cells depleted of RalGAP, epidermal 
growth factor (EGF) treatment resulted in an increased level of Ral activation and a decreased rate of 
termination of activation, leading to sustained Ral activity in stimulated cells [26]. Therefore, we 
compared the kinetics of endogenous Ral-GTP formation in response to EGF in WT versus Rce1
-/-
 MEFs.  
We stimulated serum-starved WT and Rce1
-/-
 MEFs with EGF and then monitored the GTP-bound 
levels of RalA and RalB over time by pulldown analyses (Fig. 2-4B). While the activity of both RalA and 
RalB increased in response to EGF stimulation and returned to near-basal levels at the same rate in both 
cell types, we did find that EGF stimulation caused a significantly greater initial increase in RalA-GTP 
and RalB-GTP activity in Rce1
-/-
 MEFs compared to WT MEFs (Figs. 2-4C and 2-4D). Thus, the Ral 
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mislocalization that we observed in Rce1
-/-
 MEFs is more likely to alter their regulation by one or more of 
the 6 RalGEFs than by RalGAPs [134].  
 
 
 
 
 
Figure 2-4. RCE1 deficiency increases activated Ral-GTP formed upon EGF stimulation. A, Endogenous levels 
of RalA-GTP and RalB-GTP were compared in WT, Rce1
-/-
 and Icmt
-/-
 MEFs by a pulldown assay using GST-Sec5 
RBD. Western blot analyses were done with anti-RalA or anti-Ral antibody to determine levels of Ral-GTP and total 
Ral proteins. -actin was used to verify equivalent total protein loading. B, WT and Rce1-/- MEFs were serum-
starved then stimulated with EGF. Cells were lysed at the indicated time points, followed by western blot analyses 
as described in panel A. C, RalA-GTP and D, RalB-GTP expression levels were quantified by densitometry of 
western blot data in panel B and normalized to total RalA and RalB, respectively. 
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Icmt regulates RalB stability – As described above, we observed that levels of endogenous RalB but 
not RalA proteins were stably elevated in Icmt
-/-
 MEFs compared to WT MEFs (Fig. 2-4A). Previous 
studies demonstrated that RhoA protein was destabilized upon pharmacologic inhibition or genetic loss of 
ICMT, whereas Ras protein was stabilized [145, 146]. While we did find that the steady-state transcript 
levels of RalB were slightly greater in Icmt
-/-
 MEFs compared to WT MEFs (Fig. 2-5A), this small change 
likely was an insufficient basis for the large difference in abundance of RalB protein in the two cell types 
(Fig. 2-5B). We therefore hypothesized that the increases in RalB protein in Icmt
-/-
 MEFs were due to 
altered regulation of RalB stability in the absence of ICMT.  
To investigate if RalB turnover was affected by loss of ICMT, we treated WT and Icmt
-/-
 MEFs with 
cycloheximide to block protein synthesis and then measured changes in protein levels as the preexisting 
RalB protein was degraded over time. We found that RalB exhibited a shorter half-life in WT MEFs 
compared to Icmt
-/-
 MEFs, with only 20% RalB protein remaining in WT MEFs after 18 h of 
cycloheximide treatment compared to ~60% in Icmt
-/-
 MEFs (Fig. 2-5C). This difference indicates that 
ICMT regulates RalB protein stability and promotes its degradation.  
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Figure 2-5. ICMT deficiency increases RalB protein stability. A, RalB transcript levels were determined by 
TaqMan qPCR analysis and normalized to GABPB1 in a triplicate set of assays ± SE. Data displayed as relative to 
WT MEFs. B, Endogenous RalB protein levels were quantified by densitometry of western blot and normalized to 
total protein. Data displayed as relative to WT MEFs. Experiment performed in triplicate. C, WT and Icmt
-/-
 MEFs 
were treated with 25 µg/mL cycloheximide and lysed at the indicated time points. Lysates were probed by western 
blot for total RalB, c-Myc, and for GAPDH to verify equivalent total protein. Protein levels from blots in panel were 
quantified by densitometry and normalized to 0 h. 
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Dual lipid modification of the Ral CAAX motif affects RalB subcellular localization – In addition to 
the conventional modification pathway involving RCE1 and ICMT, RalA and RalB can also undergo an 
alternative pathway, whereby the newly GGTaseI-modified protein does not undergo subsequent RCE1-
mediated proteolytic removal of the A1A2X residues but instead undergoes palmitoylation of the cysteine 
residue at the A1 position [76]. While the mechanism that regulates which pathway will be taken has not 
been elucidated, it was reported that the level of palmitoylation of RalA was increased in RCE1-deficient 
MEFs. Thus, impairment of one pathway can then favor a shift to the other pathway. We hypothesized 
that the altered subcellular localization of RalA and RalB that we observed in Rce1
-/-
 MEFs (Fig. 2-1) 
might reflect not only loss of the RCE1- and ICMT-catalyzed modifications but additionally reflect 
alterations in dual lipidation by geranylgeranylation and palmitoylation of the CAAX motif. 
To determine a role for this alternative dual lipid modification pathway in regulating RalA and RalB 
localization, we first generated the same palmitoylation-deficient Ral mutants utilized by Nishimura and 
Linder in defining the pathway [76].  To do so, we introduced a C to S amino acid substitution at the A1 
position of each Ral isoform (C204S), designated RalA-CSIL and RalB-CSLL. This substitution ablates 
palmitoylation but not geranylgeranylation of the CAAX motif [76]. Although we did not observe a 
significant alteration in RalA-CSIL subcellular localization compared to WT RalA, we did find reduced 
association of RalB-CSLL with the plasma membrane, along with increased cytosolic accumulation (Fig. 
2-1A, 2-6A). To address the role of geranylgeranylation in Ral localization, we generated nonprenylatable 
RalB-SCLL and RalA-SCIL C203S mutants that are deficient in both the geranylgeranyl and palmitate 
modifications. As expected [75], we found that these mutants were completely disrupted in both plasma 
membrane and endomembrane localization, and showed a diffuse cytoplasmic distribution including 
nuclear accumulation (Fig. 2-6B). We used our MATLAB image processing script to quantify the spatial 
distribution of the nonpalmitoylated and nonprenylated mutant Ral proteins (Fig. 2-6C). We found that 
the alternative dual lipid modification site of the RalB but not the RalA CAAX motif affects subcellular 
localization to the plasma membrane. In support of this conclusion, analysis of palmitoylation of 
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endogenous RalA and RalB revealed that the level of RalB palmitoylation is approximately two-fold 
greater than that of RalA (Fig. 2-6D and 2-6E). An explanation of this result is that disruption of the 
palmitoylatable cysteine of RalB also disrupted prenylation. To address this, we inhibited 
geranylgeranylation of the palmitoylation-defective RalB-CSLL mutant with the pharmacological 
GGTaseI inhibitor GGTI-2017.  This treatment resulted in a localization similar to that of the 
nongeranylgeranylated mutant RalB-SCLL (Fig. 2-6F). We conclude that disruption of the 
palmitoylatable cysteine does not disrupt geranylgeranylation. 
 
Figure 2-6. CA1AX palmitoylation dictates RalB subcellular localization. WT MEFs were transiently transfected 
with an expression construct encoding either nonpalmitoylatable or nonprenylatable CAAX mutants of EGFP-RalA 
or EGFP-RalB, and then visualized by confocal microscopy. A, Nonpalmitoylatable C204S CA1AX mutants (RalA-
CSIL or RalB-CSLL) or B, Nonprenylatable C203S SAAX mutant (RalA-SCIL or RalB-SCLL).  C, Images from A 
and B were analyzed using our MATLAB image processing script. D, Hydroxylamine (NH2OH)-sensitive 
palmitoylated proteins from WT MEF lysates were immobilized on thiopropyl-Sepharose resin using resin assisted 
capture (acyl-RAC), and palmitoylation of RalA and RalB was detected by immunoblotting. E, Palmitoylation 
stoichiometry was calculated by a ratio of the precipitate intensity to the input intensity. Data represent the mean ± 
S.E. (n = 6). F, WT MEFs were transiently transfected with the nonprenylatable C203S mutant EGFP-RalB-CSLL 
as in panel B, but then treated with 25 µM GGTI-2017 or DMSO control for 24 h before visualization by confocal 
microscopy. 
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Discussion 
Despite their significant sequence, structural, and biochemical similarities, RalA and RalB often serve 
divergent roles in normal and neoplastic cell functions [132-134, 147]. In this study, we determined 
whether the CAAX-signaled posttranslational modifications of proteolysis, isoprenylcysteine 
carboxylmethylation, and CAAX motif palmitoylation could contribute to the distinct regulation of RalA 
and RalB. We found that both RalA and RalB require RCE1 function for association with the plasma 
membrane but not with endomembranes. In contrast, ICMT deficiency disrupted RalB association with 
the plasma membrane, whereas it disrupted RalA association with endosomes. Assessing the 
consequences for Ral regulation, we found that RCE1 deficiency increased the steady-state activation 
state of both RalA and RalB, whereas ICMT deficiency regulated protein stability of RalB, but not RalA.  
Finally, we determined that the A1 cysteine in the CA1A2X motif that leads to alternative modification by 
the fatty acid palmitate was more significant for RalB localization than for RalA. (Ral proteins do not 
contain the upstream palmitoylatable cysteines present in the HVR of many Ras family small GTPases 
[3].) We conclude that the differential roles of CAAX-signaled posttranslational modifications contribute 
significantly to the distinct regulation of RalA and RalB.  
Previous reports have reached conflicting conclusions regarding the contribution of CAAX-signaled 
postprenyl modifications in promoting proper subcellular localization and membrane association of small 
GTPases. One study showed that both RCE1 and ICMT were critical for localization of farnesylated but 
not geranylgeranylated Ras and Rho proteins [143], whereas we found that loss of either RCE1 or ICMT 
did significantly impact the subcellular localization and membrane association of geranylgeranylated Rho 
GTPases [148].  Although total membrane-bound RalA was shown previously to be unaffected by loss of 
ICMT, its differential membrane compartmentalization was not examined, and neither the membrane 
association nor localization of RalB was investigated [143].  In the present study, we have demonstrated 
that the geranylgeranylated proteins RalA and RalB also require RCE1 and ICMT for proper subcellular 
localization. Thus, we conclude that the specific prenyl group modifying CAAX-containing proteins is 
not sufficient by itself to predict dependency on RCE1- and ICMT-catalyzed modifications. Since our 
 59 
 
studies utilized RCE1- and ICMT-deficient cells, we recognize that the consequences of their loss on Ral 
subcellular localization may be indirect and not due specifically to disrupted modification of Ral itself. 
However, since no known CAAX-terminating proteins have been described that interact with Ral, we feel 
that our results do likely demonstrate direct roles of these modifications in Ral function. 
Although RalA and RalB both localize to the plasma membrane and to endosomes, they exhibited 
striking differences in the requirement of RCE1 and ICMT to facilitate their association with these two 
membrane compartments. Loss of RCE1 disrupted association of both RalA and RalB with the plasma 
membrane but not with endosomal membranes. In contrast, loss of ICMT disrupted RalB but not RalA 
plasma membrane association, while conversely disrupting endosome localization of RalA but not RalB. 
Utilizing chimeric Ral proteins, we determined that this differential regulation was due to sequence 
divergence in the HVR rather than in the G-domain. Both HVRs are largely lysine-rich sequences and 
contain no other obvious membrane targeting information. Therefore, how each HVR impacts the 
different consequences of ICMT deficiency is not clear. However, they do diverge in the location and 
sequence context of the serines that serve as phosphorylation sites for an isoform-specific variety of 
protein kinases [71, 72, 80-82]. We conclude that inhibition of ICMT is a possible approach to blocking 
endosomal RalA function, and that this would provide a level of selectivity over inhibition of RCE1. 
Endosomal RalA function is important for cell processes including exocytosis [135, 149], cytokinesis 
[136], and cell polarity maintenance [70]. Although it is unclear why prenylation of RalA followed by 
RCE1 processing alone is sufficient to take RalA to the plasma membrane, we previously found that the 
RhoB small GTPase also showed the same dependency [148]. Thus, with some prenylated proteins, 
carboxylmethylation is dispensable for plasma membrane association. It is also possible that, since ICMT 
has additional substrates compared to RCE1, mislocalization of these other proteins may be affecting 
RalA and RalB differently. 
In addition to altered subcellular localization, we also observed consequences for Ral activation in 
RCE1-deficient cells. We found that loss of RCE1 enhanced the steady-state activity of RalA and RalB.  
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We speculated that this altered activity is a consequence of their altered subcellular localization and 
therefore of their interaction with RalGEFs or RalGAPs. Our analyses found that the kinetics of Ral-GTP 
formation upon EGF stimulation was consistent with increased activation by RalGEFs rather than 
decreased inactivation by RalGAPs. Since Ral proteins are displaced from the plasma membrane in Rce1
-
/-
 MEFs, there could be increased exposure of Ral to specific RalGEFs on internal membranes. For 
example, the RalGEF RGL2 is enriched on recycling endosomes [149]. We conclude that RCE1 
deficiency leads to aberrant RalA and RalB activation, and suggest that therapeutic intervention targeting 
RCE1 in Ras-dependent cancers could have pitfalls in unintentional Ral effector pathway activation. 
Another consequence of the loss of CAAX-signaled modifications was the increased steady-state 
level of RalB protein but not RNA in Icmt
-/-
 MEFs. Previous studies reported that ICMT-deficient, mutant 
K-Ras-transformed MEFs exhibited increased Ras protein stabilization but conversely a decreased half-
life of RhoA protein but not RNA. However, no mechanistic basis for these observations was described 
[145]. While ubiquitination of Ral has been implicated in Ral-dependent lipid raft trafficking [84], a 
degradation mechanism for Ral has not been described. Perhaps RalB interaction with an E3 ubiquitin 
ligase controlling Ral stability is affected by mislocalization associated with loss of ICMT. Alternatively, 
the absence of the methylation modification, independent of altered localization, may alter RalB 
interaction with an E3 ligase.  Consistent with this possibility, there is evidence that prenylcysteine 
methylation of CAAX-containing proteins can also play a role in regulating protein-protein interactions 
[150-153]. In summary, our observations provide the first evidence that RalB protein stability may be 
regulated by a posttranslational mechanism.   
Pharmacologic inhibition of CAAX-signaled modifications has been pursued extensively as an 
approach to inhibit Ras for cancer treatment. Initial efforts targeted the first step, catalyzed by 
farnesyltransferase. Unexpectedly, farnesyltransferase inhibitors (FTIs) were ineffective in blocking the 
membrane association of K-Ras and N-Ras, due to FTI-induced alternative prenylation by GGTaseI [154, 
155]. Since blocking Ras membrane association remains an attractive approach [156], pharmacologic 
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inhibition of RCE1 and ICMT has been considered. Initial cell-based studies using RCE1- or ICMT-
deficient MEFs found that K-Ras-induced growth transformation was impaired [116, 145 ]. However, 
subsequent mouse model studies indicate context-dependent consequences. In a mouse model of K-Ras-
induced myeloproliferative disease, loss of ICMT ameliorated tumor growth whereas loss of RCE1 
accelerated it [124, 157]. More recently, it was found that ICMT deficiency enhanced K-Ras-driven 
pancreatic cancer development [125]. A logical explanation for these different consequences for Ras-
driven oncogenesis is that ablation of RCE1 or ICMT expression alters the function of other CAAX-
terminating prenylated proteins, including small GTPases such as Ral and Rac that function downstream 
of Ras effector signaling, or of Ras family proteins that can act as tumor suppressors [158]. In conclusion, 
given the large number of other RCE1 and ICMT substrates, the usefulness of pharmacologic inhibitors 
of RCE1 and ICMT as anti-Ras drugs will likely be highly context-dependent. 
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Chapter 3: Targeting TBK1 in KRAS-mutant  
Pancreatic Ductal Adenocarcinoma 
 
Background 
Genetic ablation of Ral function has been shown to impair the development and growth of RAS-
mutant cancers [89, 132, 134].  Therefore, Ral inhibition may be a viable strategy to block Ras for cancer 
treatment [134]. However, directly targeting Ral GTPases presents the same challenges associated with 
directly inhibiting Ras.  Like Ras, Ral also has a high binding affinity to GTP and a relatively smooth 
protein surface with few to no hydrophobic binding pockets to accommodate a potent and selective small 
molecule inhibitor[139]. While several approaches have been taken to overcome these obstacles and 
directly target Ras and Ral [139, 159, 160], whether these can be advanced to clinically useful inhibitors 
is unclear.  Therefore, as with Ras, indirect approaches for blocking Ral function are being considered as 
points of intervention. In Chapter 2, I examined the potential for targeting CAAX motif-signaled 
processing enzymes that are anticipated to contribute to regulating Ral subcellular localization and 
interaction with specific membrane compartments.  Altered localization in turn may regulate Ral 
interaction with specific effectors, leading to altered signaling and biological activity.  Here, I examine 
another possibility, inhibiting Ral effector signaling. While the best-characterized Ral effectors are 
RalBP1/RLIP72 (a RhoGAP) and the Sec5 and Exo84 subunits of the exocyst complex [134, 161], these 
are also not considered highly tractable drug targets.  Instead, since protein kinase inhibitors represent the  
 
1
This work was performed in collaboration with research scientists at Eli Lilly and Company. All figures 
represent the work of Leanna R. Gentry except Figures 3-1 – 3-3. 
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most successful class of targeted therapies for cancer, I focused on inhibiting the TRAF family member-
associated NF-kappa-B activator (TANK) binding kinase 1 (TBK1), a kinase known to be a downstream 
effector of RalB. 
TBK1 is an atypical member of the IκB kinase (IKK) family with a normal role in innate 
immunity. It is a mediator of signaling through Toll-like receptor (TLR), leading to activation of 
interferon regulatory factors that control transcription of genes involved in immune response[162]. TBK1 
was discovered less than two decades ago in a yeast-two-hybrid screen to identify binding partners of 
TANK, and was found to function in a TBK1-TANK-TRAF2 (TRAF2: TNF receptor-associated factor 2) 
complex, where its activity was required to mediate TANK activation of NF-κB [163]. Since then, several 
modes of TBK1-dependent NF-κB activation have been identified. Phosphorylation of IRF3 by TBK1 has 
been shown to activate TNFα and subsequently NF-κB[164, 165]. TBK1 activity has also been shown to 
play a role in phosphorylation and subsequent degradation of IκBα, thus releasing NF-κB to allow 
translocation to the nucleus. Despite these discoveries, the precise mechanism by which TBK1 activity 
regulates NF-κB still is not fully understood, and it is becoming apparent that it is highly context-
dependent[166]. 
Aberrant activation of TBK1 has been implicated in numerous cancers, including breast[167, 
168], lung [62, 169, 170], pancreatic[171], and skin[172]. Since its identification as a potential 
requirement for cancer cell growth driven by mutant K-Ras [62], TBK1 has gained traction as a potential 
target in the treatment of cancer. Studies have elucidated how TBK1 functions downstream of Ras in 
cancer. The RalB-Sec5 effector complex has been shown to recruit TBK1and decrease apoptosis 
induction by stress on the cell[61], and this complex can also initiate IRF3 response to viral infection[85]. 
Furthermore, TBK1 activation downstream of an integrin αvβ3-K-Ras-RalB signaling pathway has been 
shown to promote tumor cell anchorage independent growth and resistance to receptor tyrosine kinase 
(RTK) inhibitors [173]. 
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This growing line of evidence for the involvement of TBK1 activity in promoting cancer has led 
to the development of pharmacologic inhibitors targeting TBK1[174, 175]. In this chapter, I study the 
effect of a novel TBK1 inhibitor, LSN3090729, on cancer cell growth and signaling, and explore 
combining the inhibitor with other targeted therapies to find a method of achieving greater efficacy in 
decreasing PDAC cell growth. 
Introduction 
TANK-binding kinase 1 (TBK1) is a noncanonical IκB kinase with a pivotal role in regulating 
cellular host defense mechanisms. In response to inflammatory cytokines and Toll-like receptor (TLR) 
activation, TBK1 is activated and phosphorylates substrates including interferon regulatory factor 3 
(IRF3) to induce transcription of genes that mediate the innate immune response [162, 176]. Interestingly, 
there is increasing evidence of aberrant activation of TBK1 having a role in cancer cell proliferation and 
survival, and the kinase has therefore gained traction as a possible therapeutic target for cancer. 
TBK1 is overexpressed in pancreatic, colorectal, breast, and lung cancer, and its aberrant 
activation has been shown to play a role in proliferation and survival of cancer cells [61, 169, 177, 178]. 
Specifically, TBK1 can be activated by the RalGEF (Ras-like GTPase guanine nucleotide exchange 
factor) effector pathway downstream of Ras, whereby RalB engages exocyst component Sec5, promoting 
Sec5 binding to and activation of TBK1 [61]. TBK1 then phosphorylates of various effectors, including 
Sec5, which ultimately leads to BCL-xL (B-cell lymphoma extra-large) and NF-κB (nuclear factor κB) 
activation and subsequent transcription of survival genes [61, 178, 179]. While TBK1 has been shown to 
be important for cancer growth and maintenance, the exact mechanisms governing cancer cell dependence 
on TBK1 activity remain unclear. Studies have shown certain cancer cells harboring K-Ras mutations 
require TBK1 for survival while others demonstrate that TBK1 is dispensable in other Ras-mutant cell 
lines [62, 171, 180].  
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Here, we seek to further understand the role of TBK1 activity in promoting cancer, and 
specifically address its function in pancreatic ductal adenocarcinoma (PDAC) growth. Since PDAC, a 
highly lethal cancer with limited treatment options, is characterized by an oncogenic K-Ras mutation in 
greater than 90% of cases, inhibition of TBK1 has been considered as an approach in the treatment of the 
disease. Inhibitors against the major effector pathways of Ras, including the Raf-MEK-ERK and PI3K-
Akt pathways, have thus far proven ineffective in reducing tumor burden, leading to an alternative 
approach of targeting the RalGEF-Ral pathway, which has been implicated in PDAC tumorigenesis and 
metastasis[105, 181]. TBK1 is one of two kinases defined downstream of the RalGEF-Ral signaling axis 
and therefore is considered one of the most tractable targets in this pathway[134].  
The emerging evidence of a role for TBK1 in human cancers as well as continued interest in its 
infection response mechanism has led to development of small molecule inhibitors targeted against TBK1 
kinase activity. The first such inhibitor, BX795, was originally discovered as a PDK1 inhibitor, and its 
amino-pyrimidine component is a base found in newer compounds that have allowed for the probing of 
the role of TBK1 [171, 174, 175, 182]. BX795 and a less promiscuous inhibitor, AZ909, were shown to 
inhibit clonogenic colony formation of N-Ras-mutant melanoma cell lines [172]. Studies of recently 
discovered inhibitors have begun to define TBK1-dependent mechanisms in cancer cells [172, 183, 184]. 
However, the efficacy seen due to TBK1 inhibition in certain systems is not applicable to all cancers. One 
study of  genetic and pharmacologic inhibition of TBK1 showed that inhibiting TBK1 activity, measured 
by disruption of IRF3 phosphorylation, is not sufficient for growth inhibition of PDAC cells, suggesting 
that a combination therapy approach may be necessary for the therapy to be effective [180].  
Here, we used a novel TBK1 inhibitor to further explore the effect of inhibiting TBK1 in PDAC 
cells. We surveyed a large panel of cancer cell lines and found that, despite inhibiting TBK1 enzymatic 
activity, treatment with LSN3090729 had a minimal and Ras-independent effect on their anchorage-
dependent proliferation. Minimal impact on anchorage-independent proliferation was also observed in a 
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panel of lung cancer cell lines as well as tumor xenografts of skin, lung, and pancreatic cancer. We found 
only a small subset of PDAC cell lines tested were sensitive to LSN3090279. Previous studies both in 
PDAC and in the context of TBK1 show that single-agent inhibition is ineffective, suggesting that 
combination approaches may be necessary. Interestingly, addition of ERK inhibition to TBK1 inhibition 
produced a synergistic decrease in anchorage-dependent proliferation and also induced apoptosis in 
resistant lines. The results of our study suggest that combined TBK1 and ERK inhibition may be effective 
in reducing PDAC growth. 
Experimental procedures 
Cell  lines  and plasmids – PDAC cell lines were obtained from ATCC and maintained in either DMEM-
H or RPMI-1640 supplemented with 10% fetal calf serum. A validated short hairpin RNA (shRNA) 
sequence shT15 for human TBK1 was provided by Dr. Paul Kirschmeier (Dana-Farber Cancer Institute) 
and was cloned as previously described [180]. 
Inhibitor treatment assays – Sensitivity of PDAC cells to LSN3090279, alone or in combination with 
SCH772984, was determined by MTT assay. Briefly, LSN3090279 was serially diluted from 10 μM to 
0.019 μM in a 96 well plate with or without a constant concentration of SCH772984. Cells were seeded at 
a density of 3 x 10
3
 cells per well and allowed to proliferate at 37°C and 5% CO2 for 72 hours. Then, 
cells were treated with 5 mg/mL MTT for 4 hours at 37°C and formazan crystals were then solubilized 
with DMSO. The absorbance at 550 nM was recorded.  
2D clonogenic growth assays were performed by seeding cells in 6 well plates at 500 to 1,000 
cells per well. Cells were allowed to adhere for 24 hours and were then treated with varying 
concentrations of LSN3090279 for 10 days. Colonies were stained with 2 mg/mL crystal violet in 4% 
paraformaldahyde for 10 min and counted using Image J. 
Immunoblotting – Cells were lysed in NP40 buffer supplemented with protease inhibitor cocktail and 
phosphatase inhibitor cocktails. Protein concentration was determined by a Bradford Protein Assay (Bio-
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Rad). Proteins were separated by SDS-PAGE gel electrophoresis, transferred to PVDF (Immobilon), and 
probed with either anti-TBK1 (Cell Signaling), anti-phospho-TBK1 S172, anti-IRF3 (Cell Signaling 
D83B9), anti-phospho-IRF3 S396 (Cell Signaling 4D4G), anti-GAPDH, anti-LC3, anti-cleaved caspase-3 
(Cell Signaling), anti-RSK (Cell Signaling 32D7), or anti-phospho-p90RSK S380 (Cell Signaling 9D9). 
Blots were imaged with the BioRad ChemiDoc and analyzed using Image Lab and ImageJ software. 
Results 
LSN3090279 is a TBK1 inhibitor – We synthesized LSN3090279, a 4-aryl-2-aminopyrimidine derivative, 
and have characterized the compound as a selective TBK1 kinase inhibitor with an in vitro IC50 ranging 
from 19 nM to 73 nM (data not shown). We tested LSN3090279 for inhibition of a panel of over 100 
kinases and found minimal off-target effects (Fig. 3-1A, 3-1C).  
We further characterized LSN3090729 by testing its ability to inhibit TBK1 signaling to known 
phosphorylation targets IRF3 and Akt in cells. First, we stably expressed TLR4 and IRF3 in HEK293 
cells to ensure the known upstream and downstream components of the TBK1 signaling pathway were 
intact in our model system. We then stimulated TBK1 activity by treatment with lipopolysaccharide 
(LPS) and used an Acumen-based assay to measure the ability of LSN3090729 to block LPS-induced 
TBK1-mediated phosphorylation of its direct substrate IRF3 (Fig. 3-1B). LSN3090729 blocked 
phosphorylation of IRF3 with an IC50 of 125 nM. To extend our cellular analysis, we compared genetic 
depletion of TBK1 to pharmacologic inhibition of its kinase activity and examined downstream TBK1 
signaling to Akt. We either stably suppressed TBK1 expression by shRNA or inhibited TBK1 kinase 
activity with LSN3090729 in Panc1 cells (Fig. 3-1D and 3-1E). We then treated cells with 100 ng/mL 
EGF and confirmed that phosphorylation of Akt that was dependent on TBK1 expression was also 
reduced in the presence of LSN3090729 (Fig. 3-1E). Collectively, these results show that LSN3090279 is 
active in the cell and is inhibiting TBK1 signaling. 
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Figure 3-1. LSN3090729 inhibits TBK1. A) LSN3090729 discovered as a TBK1 inhibitor with IC50 0.019-0.073 
μM.  B) LSN3090729 has cellular activity. It inhibits LPS-induced phosphorylation of IRF3 in HEK293 cells. C) 
Off-target effects under 1 M. D) TBK1 shRNA and E) LSN3090729 inhibits EGF-mediated AKT phosphorylation 
in Panc1 cells. F) LSN3090729 pharmacokinetic profile in rats. 
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LSN3090279 has a minimal effect on cancer cell proliferation in vitro and in vivo – The effect of TBK1 
depletion or inhibition of cell proliferation across different cancer types may be highly context-dependent. 
TBK1 was shown to be dispensable for the proliferation of a panel of K-Ras-mutant-containing PDAC 
cells but was required for K-Ras-dependent lung cancer cell proliferation [62, 180]. Furthermore, separate 
studies have provided conflicting evidence regarding whether TBK1 inhibition is lethal to cells in Ras-
dependent cancers. To investigate this further, we sought to determine the impact of TBK1 inhibition by 
LSN3090729 on cancer cell proliferation, and whether this dependence on TBK1 was dictated by the 
presence of an activating Ras mutation. To address this, we treated a panel of over 300 cancer cell lines of 
varying Ras mutation status with LSN3090279 from 0 to 20 μM and assessed its anti-proliferative activity 
in 2D culture. We found a large range of GI50 values (where GI50 is the concentration required for 50% 
growth inhibition), with the majority of cells displaying a GI50 > 10 μM and with GI50s not dependent 
on Ras mutation status (Fig. 3-2A). We extended this study to examine the effects of LSN3090729 on 
anchorage-independent growth in a select panel of cancer cell lines (Fig. 3-2B). Again, we found 
dependence on TBK1 did not correlate with Ras mutation status. Overall, LSN3090279 was found to 
have only a minimal effect on cancer cell proliferation in vitro.  
 
Figure 3-2. LSN3090729 has K-Ras-independent effect on cancer cell growth. A) Panel of cancer cell lines used 
in 2D Cell-TiterGlo assay (grey: mutant K-Ras; black: wild-type K-Ras) B) Panel of cancer cells in 3D soft agar 
assay (grey: mutant K-Ras; black: wild-type K-Ras) 
  
 70 
 
PDAC cell lines show varying sensitivity to pharmacologic TBK1 inhibition – Our data suggest that the 
efficacy seen with TBK1 inhibition is not solely dependent on the presence of a Ras mutation. However, 
TBK1 is a known mediator of Ras signaling and remains a tractable target due to its kinase activity. 
Therefore, it remains a potential therapeutic target for Ras-driven cancers. Because of this, we chose to 
study the effect of LSN3090729 in PDAC, a cancer characterized by an oncogenic K-Ras mutation in 
greater than 90% of cases. We determined the impact of LSN3090729 on proliferation of PDAC and 
normal immortalized pancreatic epithelial cells. Anchorage-dependent proliferation was measured after 
treatment with LSN3090729 for 72 hours (Fig. 3-3A). We found that only two PDAC cell lines, Panc1 
and HPAC, were sensitive to TBK1 inhibition (GI50 of 2.59 μM  and 3.41 μM , respectively) while six 
PDAC cell lines and the two normal pancreas cell lines were considered insensitive (GI50  > 8 μM). 
However, LSN3090729 was found to decrease phosphorylation of IRF3 serine 396 at IC50 values near 2 
μM in both the sensitive and resistant lines (Fig. 3-3C and 3-3D). This demonstrates that TBK1 was not 
always sufficient to reduce proliferation, consistent with previous studies showing differential effects on 
the proliferation of PDAC cell lines upon TBK1 inhibition [180]. Cell lines identified as sensitive in 2D 
culture also showed greater response to inhibitor treatment in clonogenic assays compared to resistant 
lines (Fig. 3-3B). These sensitivity differences observed in clonogenic assays were not reflected upon 
depletion of TBK1 by shRNA. However, given that the TBK1 scaffolding function may have different 
effects on downstream signaling than its enzyme activity does, this result is not surprising and is 
supported by previous results showing no impact on PDAC cell growth using this TBK1-targeting 
sequence (Fig. 3-4B).  
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Figure 3-3. PDAC cells are resistant to LSN3090279. A) IC50 of PDAC cells treated with LSN3090279 and 
analyzed at 72 hours using an MTT assay. B) Cells were seeded for clonogenic assays on day 0, treated with 
LSN3090279 at indicated concentrations on day 1, and colonies were quantified at day 10. C) Sensitive and D) 
resistant PDAC cells were probed as indicated at 72 hours post-treatment with LSN3090279. 
  
 72 
 
 
Figure 3-4. TBK1 depletion does not decrease colony formation. A) TBK1 was stably knocked down by shRNA. 
B) Cells were seeded for clonogenic assays on day 0 and colonies were quantified at day 10. 
 
While TBK1 has an autophosphorylation site at serine 172, this has been found to not be 
indicative of TBK1 activation, contrary to what is often found in other kinases [174]. Instead, it was 
previously determined that IRF3 phosphorylation levels are elevated chronically in PDAC cells and that 
phosphorylation of IRF3 serine 396 is a reliable marker of TBK1 inhibition [180]. We sought to 
determine if inhibition of phosphorylation of IRF3 or TBK1 by LSN3090729 correlated with sensitivity 
to growth inhibition using two sensitive and two resistant PDAC cell lines. We found that reduction in 
phosphorylation of IRF3 tracked closely with increasing doses of LSN3090729, whereas varying effects 
on TBK1 phosphorylation were observed (Figs. 3-3C and 3-3D), which is also consistent with previous 
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studies. Furthermore, in our two sensitive cell lines, Panc1 and HPAC, we observed that 50% inhibition 
of TBK1 as measured by phosphorylation of IRF3 (IC50) correlated with GI50. Conversely, the IC50 of 
two resistant cell lines, SW1990 and Capan1, was much lower than that of the GI50. These results 
suggest that, while IRF3 phosphorylation is a reliable marker of TBK1 inhibition by LSN3090729, 
inhibition of IRF3 phosphorylation does not always correlate with TBK1-dependent proliferation in 
resistant cells. 
Interestingly, upon treatment with LSN3090729, we observed a rapid formation of large vacuoles 
that remained unresolved after 96 hours (Fig. 3-5A), although these vacuoles did not form after depletion 
of TBK1 by shRNA. Due to the known role of TBK1 in autophagy and the relation of these vacuoles to 
autophagolysosome formation in previous studies, we sought to determine if autophagy was misregulated 
in LSN3090729-treated cells [170, 185-187]. We observed an increase in total LC3BI and LC3BII as well 
as an increasing ratio of LC3BII to LC3BI, indicating that autophagy was induced and that lysosomal 
clearance was disrupted (Fig. 3-5B). Further work is required to determine the effect of this 
LSN3090729-dependent regulation of autophagy on cancer cell proliferation and survival. 
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Figure 3-5. LSN3090729 disrupts autophagy in PDAC cells. A) Indicated PDAC cell lines were treated with 
increasing doses of LSN3090729. Cells were imaged at 24 hours. B) Cells were treated with LSN3090279 for 72 
hours and probed for LC3B I and II. 
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Mounting evidence suggests that differing effects of inhibitor treatment are often observed in 
cancer cells in vitro versus in vivo due to tumor microenvironment and heterogeneity [188-190]. 
Therefore, we examined the effect of LSN3090729 on tumor growth to determine if the sensitivity 
observed in selected PDAC cell lines was recapitulated in a xenograft mouse model. Pharmacokinetic 
analysis showed that LSN3090279 has over 70% oral bioavailability and an acceptable half –life of 1.7 
hours in rats (Fig. 3-1F). In a pancreatic cancer Panc1 xenograft mouse model, a modest decrease in 
tumor growth was observed upon treatment with LSN3090729 compared to vehicle control (Fig. 3-6A). 
We extended this to colorectal cancer HCT116 and lung cancer A549 mouse xenograft models. In the 
colorectal cancer model, a slight decrease in tumor growth was observed at a higher dosing regimen (Fig. 
3-6C). In the lung cancer model, a minimal effect was seen upon treatment with LSN3090729. In the lung 
cancer model, treatment with LSN3090279 caused only a minimal tumor growth delay, whereas treatment 
with the PI3K/mTOR inhibitor BEZ-235 dramatically decreased tumor size (Fig. 3-6B).  
 
Figure 3-6. LSN3090729 minimally affects K-Ras-mutant tumor xenografts. A) Mice bearing subcutaneous 
Panc1 tumors in a pancreatic cancer model were dosed with vehicle or a single dose of LSN3090729. Each study 
group had 10 mice. B) Mice bearing subcutaneous A549 tumors in a lung cancer model were dosed with vehicle, 
LSN3090729, or PI3K/mTOR inhibitor BEZ-235. C) Mice with HCT116 subcutaneous tumors in a colon cancer 
xenograft model were dosed with vehicle or one of 2 doses of LSN3090729. 
 76 
 
Combined TBK1 and ERK inhibition synergistically decreases PDAC cell proliferation – Small 
molecule inhibitors against TBK1 in cancer have proven ineffective as single agents, and concurrent 
inhibition of other cancer-promoting pathways is being explored as a new approach. One study 
demonstrated that combined TBK1 inhibition with MEK inhibition in N-Ras-mutant melanoma cells 
induced apoptosis, as shown by increased PARP cleavage and annexin V staining [172]. However, it did 
not address the impact of the combination treatment on cell proliferation. Previously, we have shown 
differential growth sensitivity to MEK and ERK inhibition in PDAC cells, with ERK inhibition proving 
slightly more effective, although the majority of cells remained resistant to both inhibitors (Hayes et al, 
manuscript in preparation). We sought to determine if simultaneous inhibition of TBK1 and ERK 
impacted PDAC cell growth. 
We have previously determined that the growth of Capan1 and SW1990 cells are resistant to 
treatment with ERK inhibitor SCH772984 (GI50 > 4 μM) despite inhibition of ERK, as measured by 
phosphorylation of RSK, at almost 10-fold lower concentrations (IC50 = 450 nM) (Hayes et al, 
manuscript in preparation). We treated Capan1 and SW1990 cells with ERK inhibitor SCH772984 and 
TBK1 inhibitor LSN3090729 and measured the effect on anchorage-dependent growth over 72 hours (Fig. 
3-7A and 3-7B). Interestingly, we observed that LSN3090729 and SCH772984 acted synergistically in 
inhibiting proliferation of both cell lines. We observed an increased number of non-adherent cells upon 
simultaneous treatment with SCH772984 and LSN3090729 simultaneously compared to either inhibitor 
alone. We also observed an increase in cleaved caspase 3 in adherent cells when combining inhibitors 
(Fig. 3-7C). Therefore, we concluded that adding SCH772984 to LSN3090279 treatment results in 
induction of apoptosis in our resistant cell lines. 
We compared these results to combined inhibition of MEK using AZD6244. We previously have 
shown that anchorage-dependent proliferation of PDAC cells is resistant to AZD6244 (GI50 > 8 μM) 
despite effective disruption of signaling at 100 nM of AZD6244, demonstrated by decreased ERK 1/2 
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phosphorylation. We found that, while combining AZD6244 with LSN3090279 in treatment of our 
resistant PDAC lines did cause a further reduction in growth compared to LSN3090729 alone, this did not 
produce the same synergistic proliferation defect as observed with combined treatment of LSN3090729 
and SCH772984 (Fig. 3-7A and 3-7B). 
 
Figure 3-7. Combined TBK1 and ERK inhibition decreases resistant cancer cell growth 
synergistically.  Treatment of A) Capan1 and B) SW1990 cells with increasing doses of LSN3090729 
and either 100 nM MEK inhibitor AZD6244 or 450 nM ERK inhibitor SCH772984 gives a synergistic 
growth defect in 3 day 2D MTT assay, with combination index values in the range of 0.7 – 0.8 (<1 = 
synergy) over 40 nM – 5 μM LSN3090729. Signaling in C) Capan1 and SW1990 through pIRF3, pRSK, 
and caspase 3 cleavage. 
Discussion 
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 Mutationally activated K-Ras is a driver in over 90% of PDAC cases [103]. Despite an increased 
understanding of effector pathways mediating K-Ras-dependent cancer growth, treatment options remain 
limited [191]. With the exception of the EGFR inhibitor erlotinib, there are no approved targeted 
therapies for PDAC patients, and chemotherapy remains the standard of care. This is in contrast to other 
cancers including lung, skin, and breast, for which multiple approved targeted therapies options have 
contributed to prolonging patient survival [192-194]. While inhibitors of PI3K, Akt, and MEK have 
exhibited moderate effects on PDAC cell proliferation, the overall efficacy of these inhibitors observed in 
patients has been minimal, and other possible targets should be considered. Given the increasing evidence 
for TBK1 activity in promoting cancer, we chose to determine the effect of inhibiting this less-studied 
Ras effector in PDAC. 
 Due to the implication of TBK1 overexpression and aberrant activation in promoting numerous 
cancers, small molecule inhibitors targeting TBK1 have been developed. Inhibition of TBK1 with 
LSN3090279 had a minimal effect on a large panel of cancer cell lines in anchorage-dependent growth 
assays, independent of Ras mutation status [180]. This is contradictory to previous reports suggesting that 
inhibition of TBK1 decreases cancer cell growth selectively in Ras-dependent cells [62]. Furthermore, our 
findings agree with previous findings that TBK1 inhibition alone is not sufficient to reduce growth in 
most PDAC cell lines, although a select set of cell lines did show sensitivity to the inhibitor. Future work 
to define a biomarker that is indicative of TBK1 sensitivity could lead to a more effective implementation 
of TBK1 inhibitors. 
Multiple studies, including ours, have determined that TBK1 inhibition may be a viable approach 
for targeting Ras-driven cancers when combined with inhibition of another Ras effector pathway. We 
showed that combining ERK1/2 and TBK1 inhibition produced a synergistic growth defect in PDAC cells 
resistant to both TBK1 and ERK1/2 inhibition alone, and that this increased sensitivity was accompanied 
by an induction of apoptosis. These results agree with previous work that has shown induction of 
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apoptosis upon combined TBK1 and MEK inhibition in N-Ras-mutant melanoma cells and upon 
combined inhibition of ERK and PI3K in resistant PDAC cells [172](Hayes, manuscript in preparation). 
Inhibition of TBK1 has been shown to increase phosphorylation of ERK through feedback signaling in 
lung cancer cells, providing one explanation for the synergy seen with dual inhibition of these kinase 
pathways [177, 195]. Furthermore, ERK inhibition has been shown result in upregulation of pro-apoptotic 
signaling through BIM [196]. It is possible that inhibition of TBK1 leads to downregulation of anti-
apoptotic proteins through inhibiting NF-kB signaling, resulting in a second mechanism of permitting this 
induction of apoptosis and subsequent decrease in cell viability. Another study has shown that combined 
TBK1 and MAPK inhibition in a mouse model of K-Ras-driven lung cancer caused tumor regression and 
demonstrated that the disruption of autocrine signaling by a TBK1 inhibitor caused sensitivity in lung 
cancer cells [195]. Thus, exploring cytokine production by PDAC cells both sensitive and resistant to 
TBK1 inhibition may shed light on the TBK1-dependent mechanisms dictating PDAC cell proliferation. 
Overall, our study demonstrated that TBK1 inhibition alone in PDAC has a minimal effect on cell 
proliferation, and that combining this with inhibition of a different cancer-promoting pathway 
downstream of Ras is a viable alternative approach. Future studies combining TBK1 inhibition with 
blockade of anti-apoptotic pathways may prove efficacious in the treatment of PDAC. 
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Chapter 4: Concluding Remarks and Future Directions 
 
My work has addressed two approaches for inhibiting Ral small GTPase function and signaling for 
the treatment of RAS-mutant cancer. First, I examined inhibition of posttranslational modifications 
signaled by the RalCAAX tetrapeptide motif and catalyzed by RCE1, ICMT, and of palmitoylation, as a 
way to disrupt Ral subcellular localization and association with the plasma membrane. Second, I 
addressed targeted inhibition of a downstream effector signaling component of the RalGEF-Ral pathway, 
the TBK1 serine/threonine kinase. Here, I summarize the conclusions from these studies and discuss the 
next steps to be taken in further determining the effect of Ral inhibition in Ras-driven cancers. 
Is Ral responsible for exacerbation of KRas-driven pancreatic cancer in the absence of ICMT?  
My work shows that loss of ICMT causes subcellular mislocalization and accumulation of RalB 
in endomembrane compartments as well as disrupted degradation of RalB. However, we do not know the 
impact of this on RalB-dependent cancer growth. In previous studies, it was determined that RalB was 
critical for PDAC invasion and metastasis [105].  Although one study showed that ablation of ICMT 
decreased K-Ras-induced myeloproliferative disease and thus suggested ICMT targeting was a viable 
strategy for treating K-Ras-dependent cancers, a recent study in a K-Ras-driven pancreatic cancer mouse 
model showed that loss of ICMT resulted in accelerated PanIN progression to pancreatic ductal 
adenocarcinoma[125]. The authors concluded that this exacerbation is due to suppression of Notch. 
However, I believe that another mechanism may have a role. I hypothesize that misregulation of RalB 
plays a role in ICMT-dependent suppression of K-Ras-driven pancreatic tumorigenesis.  Rather than 
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inactivating RalB function, the absence of the carboxylmethylation modification may aberrantly activate 
RalB function or result in increased expression, hence promoting rather than inhibiting cancer growth. 
 To test this, I would use the previously-described genetically engineered Icmt flx/+; Pdx1-Cre; 
LSL-KRasG12D and Icmt flx/flx; Pdx1-Cre; LSL-KRasG12D mouse model. I would culture cells from 
mouse tumors and compare RalB localization and protein expression in tumor cells with one copy of Icmt 
versus no Icmt. Based on my studies, I would expect to see RalB mislocalized away from the plasma 
membrane and increased in expression in the tumor cells with no Icmt. If this is the case, I could then 
generate an Icmt flx/flx; RalB flx/flx; Pdx1-Cre; LSL-KRasG12D mouse model where I could observe K-
Ras-dependent tumor formation and progression to metastasis in the absence of both Icmt and RalB 
compared to an Icmt flx/+; RalB flx/flx; Pdx1-Cre; LSL-KRasG12D mouse model.  
Does loss of RCE1 exacerbate KRas-driven pancreatic cancer?   
Surprisingly, I found that absence of RCE1 resulted in mislocalization and hyperactivation of 
both RalA and RalB compared to levels found in WT MEFs. However, little is known about the impact of 
RCE1 loss on the activation of other CAAX-containing proteins. While one study has shown Icmt loss 
exacerbates K-Ras-driven pancreatic tumor formation in mice, the consequence of Rce1 loss in this model 
has not been studied [125]. Although mutationally activated Ras-induced transformation was decreased in 
Rce1
-/-
 MEFs, loss of ICMT also resulted in decreased transformation by mutationally activated Ras, 
suggesting this assay is not always indicative of protein’s role in tumorigenesis [116, 145]. To test 
whether RCE1 has an effect on mutant K-Ras-driven PDAC, I could genetically engineer a Rce1flx/flx; 
Pdx1-Cre; LSL-KRasG12D mouse model with a control model Rce1flx/+; Pdx1-Cre; LSL-KrasG12D. I 
would examine the rate of PanIN (preneoplastic lesions) progression to PDAC formation to determine if 
the loss of Rce1 accelerates PDAC tumor formation, which could be due to an increase in RalA and RalB 
activation above that caused by K-Ras G12D signaling alone.  
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Does RCE1 deficiency result in hyperactivation of other small GTPases?  
RCE1 deficiency has been shown to impact Ras function, such that transformation by 
mutationally activated Ras was decreased in Rce1
-/-
 MEFs [116]. In studies of CAAX-containing proteins 
downstream of Ras, RCE1 was found to be required for the subcellular localization of certain Rho family 
small GTPases  and of the Rheb small GTPase, but was dispensable for K-Ras4B- and Rheb-dependent 
mTORC1 activation [148, 197]. Interestingly, these studies did not address the impact of RCE1 loss on 
catalytic activity of endogenous small GTPases. Given our finding that loss of RCE1 can cause a 
significant increase in Ral activity (Fig. 2-4 A), it is worth investigating if there is a similar impact on 
other non-mutationally activated small GTPases whose functions may contribute to cancer growth. I 
would compare the consequence of RCE1 loss on GTP loading of Ras, RhoA, Rac1 and Rheb proteins, as 
all of these have been implicated in promoting cancer. Since RCE1 inhibition is being explored as a point 
of therapeutic intervention, we must be cautious of the consequences on other CAAX-terminating 
proteins with known functions as oncoproteins or tumor suppressors such as liver kinase B1 (LKB1) or 
Di-Ras1 [198, 199]. Furthermore, if this aberrant activation is observed in other small GTPases, a 
comparison of these proteins sequences, localizations, and functions could reveal why this activation is 
occurring and if there is a rational approach to safely implementing RCE1 inhibition in cancer treatment. 
What is responsible for hyperactivating RalA and RalB in Rce1
-/-
 cells?  
Although my studies demonstrated that EGF stimulation in the absence of RCE1 results in 
increased RalA- and RalB-GTP levels above those found in the presence of RCE1, the mechanism by 
which this occurs remains unknown. Since these activity levels are not sustained, this suggests that 
aberrant RalGAP regulation is not responsible, but instead that an upstream signaling pathway is likely 
involved. This leads me to hypothesize that activation by one or more RalGEFs is responsible for 
mediating this EGF signaling and hyperactivation of the Ral proteins. To address this, I would first 
express a dominant negative RalA or RalB S28N mutant protein that sequesters endogenous RalGEF 
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proteins. Stimulation of mutant-containing cells should not show a greater Ral-GTP increase in the 
absence of RCE1, showing that RalGEFs are indeed necessary for endogenous Ral to be hyperactivated in 
these cells. I could then stably knock down individual RalGEFs using shRNA in Rce1
-/-
 MEFs using a 
non-targeting shRNA as a control. I would repeat EGF stimulation in these two Rce1
-/-
 MEFs and WT 
MEFs and measure Ral activity to determine if depletion of a specific RalGEF shifts the Ral activation 
level to that observed in WT MEFs. However, these analyses are complicated by the fact that there are 
four RalGEFs that act as Ras effectors and two other RalGEFs whose mechanism of regulation is still 
unclear. 
 Alternatively, it is possible that misregulation of another small GTPase is resulting in this 
hyperactivation. RalGEFs have been shown to interact with small GTPases besides Ral, including the Ras 
family proteins, R-Ras2/TC21, and Rap1A, all of which contain CAAX motifs that are also subject to 
Rce1 processing [200, 201]. This interaction between alternative GTPases and RalGEFs could be 
disrupted, indirectly resulting in Ral hyperactivation. A study of TC21 and Rap1A dependence on RCE1 
could inform studies of RCE1-dependent Ral regulation. 
What region of RalB contributes to stabilization in Icmt
-/-
 MEFs?  
My studies showed that ICMT absence resulted in increased RalB protein stability and 
mislocalization that was dependent on the hypervariable C-terminus of RalB. Given this, in order to 
determine if a specific sequence of RalB is responsible for regulating this ICMT-dependent protein 
degradation, I would first express chimeric HA-tagged RalA/B and RalB/A in WT and Icmt
-/-
 MEFs and 
monitor degradation by blotting for HA after treatment with the protein synthesis inhibitor cycloheximide. 
I would expect RalA/B to be stabilized similarly to RalB in the Icmt
-/-
 MEFs. Phosphorylation of key 
serine residues in the C-termini of RalA and RalB by distinct protein kinases is one of the major 
differences in the Ral protein HVRs and contributes to their diverging roles [71, 72]. If I did observe that 
RalA/B is stabilized, I would determine if this is linked to phosphorylation of RalB serines 192 and 198, 
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by immunoprecipitating RalB in WT and Icmt
-/-
 MEFs and blotting for phosphorylated serine. If an 
increase in phosphorylated serine levels was observed, I would express S192A and S198A 
phosphodeficient mutants to determine if phosphorylation of a specific site is mediating this degradation 
defect. Examination of RalB protein levels in Icmt
-/-
 MEFs after mutation of these sites to 
phosphomimetic S192D and S198D could provide further insight into whether phosphorylation at these 
sites is important for efficient RalB turnover. 
Is an E3 ligase interaction being disrupted in RalB degradation?  
I observed that the steady-state level of RalB protein becomes stabilized in the absence of ICMT. 
In order to determine if this is due to an inability to be recognized by the relevant E3 ligases, WT and 
Icmt
-/-
 MEFs can be treated with the MG132 proteasome inhibitor and RalB levels monitored for 
accumulation. If this is seen, then it implicates an E3 ligase-based mechanism of RalB degradation. To 
determine if ubiquitination of RalB is deficient in Icmt
-/-
 MEFs, RalB can be immunoprecipitated and 
immunoblotted for ubiquitin. I would expect ubiquitinated RalB levels to be greater in the WT MEFs 
where efficient turnover is occurring. 
If this is observed, there could be an E3 ligase interaction disrupted by absence of ICMT. While 
there are new technologies to find targets of E3 ligases, determining the E3 ligase for a specific substrate 
is not as straightforward [202-204]. This is due in part to the transient interaction between the E3 ligase 
and its substrate that limit use of traditional techniques as well as to the little information that is known 
about the functions of the E3 ligases. To address this question, I would perform an siRNA screen against 
the 617 putative E3 ligases in WT MEFs expressing a fluorophore-tagged RalB and use a fluorescent 
readout of relative expression levels. Specifically, I could utilize the Global Protein Stability Profiling 
(GPS) genetic screening platform [204-206]. Using the GPS system, GFP-RalB and a control DsRed 
fluorescent protein would be expressed from one mRNA transcript. DsRed would serve as the internal 
control, and varying GFP-RalB levels could be measured as a GFP – to – DsRed ratio quantified by 
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fluorescence-activated cell sorting (FACs) [206]. Any E3 ligase identified as modulating RalB stability 
could be validated by repeating genetic depletion of the specific E3 and monitoring ubiquitination levels 
and protein expression of RalB by western blot. 
Does palmitoylation of the CAAX motif of Ral play a role in Ral-dependent cancer?  
Ral proteins have been shown to have roles in tumorigenesis and metastasis in vivo as well as 
anchorage-independent and -dependent growth, motility, and invasion in vitro [81, 93, 104, 105]. My 
studies showing that RalB palmitoylation of the CAAX motif is approximately twice as high as that of 
RalA and that the palmitoylation-deficient mutant RalB-CSAX is mislocalized lead one to question if 
palmitoylation of RalB is playing a role in these cancer phenotypes. To address this, I would use PDAC 
cells, since the RalB-dependent phenotype of cell invasion in this system is well-studied [105]. I would 
first express CSAX mutants to confirm the same localization patterns as observed in MEFs. I would then 
stably deplete RalA and RalB in PDAC cell lines known to be dependent on Ral for their cancer 
properties and rescue with either wild type or a palmitoylation deficient CSAX mutant. I would expect 
RalB-CSAX to not rescue invasion in PDAC cells due to its mislocalization and higher prevalence of 
RalB palmitoylation. It would also be interesting to see the impact of the palmitoylation-deficient mutant 
on RalB activity levels in cancer cells.  
Does RalB palmitoylation affect novel effector interaction? 
 While my studies identified palmitoylation of RalB as regulating its localization, the impact of 
this modification on RalB effector signaling, enzymatic activity, and contribution to RalB-dependent 
cancer phenotypes has not been addressed. One question that arises is whether palmitoylation of RalB 
causes interactions with unidentified Ral effectors or alters interactions with known Ral effectors. 
Previous studies have utilized constitutively activated RalB to identify interactors, but the effects of 
posttranslational modifications, such as palmitoylation, on protein-protein interactions have not been 
examined. To do this, I would express either WT RalB or the palmitoylation-deficient RalB-CSAX 
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mutant protein in cells. I would co-immunoprecipitate RalB and analyze the isolated product by mass 
spectrometry. Comparison of proteins in complex with RalB may identify unknown binding partners of 
RalB, thus giving more insight into the pathways downstream of Ral. Ultimately, this could inform future 
studies of the best way to target Ral in cancer. 
Does synergy found with TBK1 and ERK combined inhibition result from dual inhibition of anti-
apoptotic pathways?  
My study demonstrated that combined TBK1 and ERK inhibition resulted in an induction of 
apoptosis. While TBK1 is known to have a pro-survival role, few studies have addressed the mechanism 
by which this occurs, and it remains unclear how simultaneously inhibiting these two kinases promotes 
apoptosis. A previous study showed that TNF-induced apoptosis, demonstrated by cleaved caspase 3, was 
increased in the absence of TBK1, and that this was dependent on both phosphorylation of RelA at serine 
536 and RelA-dependent expression of transglutaminase 2 [207]. However, targeting TBK1 activity alone 
in our system was not sufficient to induce apoptosis. Furthermore, ERK inhibition alone has only a 
minimal effect on apoptosis. This is likely due to the same mechanism described in a study of MEK 
inhibition, where suppression of ERK signaling led to increased BIM expression that alone was 
insufficient to induce apoptosis. When combined with an inhibitor of an anti-apoptotic protein, however, 
apoptosis was induced [196]. I would hypothesize that combined TBK1-inhibition-dependent suppression 
of an anti-apoptotic protein and ERK-inhibition-dependent BIM upregulation lead to the synergistic 
induction of apoptosis. To test this, I could monitor protein expression of BIM and phosphorylation of 
RelA S536 as well as expression of RelA transcriptional targets after treatment with LSN3090729, 
SCH772984, or combined treatment. I would expect the increase in BIM from the combination treatment 
to be greater than the levels of BIM induced from each inhibitor alone.  
How does TBK1 inhibition affect autophagy? 
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My studies demonstrated that treatment with LSN3090279 at low doses caused large vacuole 
formation that remained unresolved after 96 hours as well as an accumulation of LC3, both indicative of 
incomplete autophagy. However, knockdown of TBK1 did not cause vacuole formation, and previous 
studies have shown TBK1 depletion causes a decrease in chloroquine-dependent LC3 accumulation [170]. 
Therefore, the mechanism by which TBK1 inhibition could deregulate autophagy is not unclear. In this 
case, it is difficult to determine if the absence of the scaffolding properties of TBK1 upon protein 
depletion by shRNA may be resulting in a different phenotype than inhibition of TBK1, or if 
LSN3090279 off-target effects are responsible. To address this, I could utilize alternative TBK1 inhibitors 
that are chemically distinct with different off-target activities. If treatment of cells with these inhibitors 
also results in vacuole formation, it is likely that it is a TBK1-dependent phenotype. Alternatively, I could 
utilize CRISPR to conditionally knock in a kinase-dead K38A mutation into TBK1 and monitor cells for 
vacuole formation. If vacuoles do not form, I would conclude this is an off-target effect of LSN3090279. 
However, if they do form, and if LC3 accumulation is observed, I could then determine if upregulation of 
autophagy was contributing to resistance of cells to TBK1 inhibition. I would first treat with 
LSN3090279 and then knock down components of the autophagy pathway and measure cell viability to 
determine if a new dependence on autophagy has occurred in the presence of TBK1 inhibition. 
Alternatively, I could starve cells resistant to TBK1 inhibition in order to induce pro-survival autophagy. 
Subsequently, I could treat with LSN3090279 to determine if resistant cells are now sensitive to TBK1 
inhibition. 
Is sensitivity to TBK1 inhibition dictated by autocrine signaling?  
Our study identified a subset of PDAC cell lines that were sensitive to TBK1 inhibition. However, 
the mechanism controlling this sensitivity remains unknown. One study demonstrated that K-Ras-driven 
lung tumorigenesis was promoted through TBK1-dependent autocrine signaling; specifically, TBK1 
depletion caused a decrease in CCL5 and IL-6 production [195]. To determine if a similar mechanism is 
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responsible for TBK1 inhibitor sensitivity, I would treat sensitive cells with either LSN3090279 or 
DMSO. I would then replace media on treated cells with conditioned media from DMSO-treated cells and 
determine if this rescued cell growth. If cell growth is rescued, I would then assess conditioned medium 
from DMSO- and inhibitor-treated cells using a cytokine antibody array to determine if any cytokines are 
depleted or elevated in inhibitor-treated media. 
Will TBK1 inhibition sensitize cancer cells to other targeted inhibition? 
Combination approaches are gaining traction in the treatment of cancer. However, toxicities 
associated with simultaneous inhibition of major Ras-dependent pathways like MEK and PI3K have 
limited this approach, and new combinations are needed to treat patients while minimizing negative side 
effects. Here, we combined TBK1 and ERK inhibition and found a synergistic proliferation defect. While 
promising, this was not sufficient to reduce cell viability past 50%. To further determine how TBK1 can 
be effectively implemented in PDAC patients, I would expand my studies to include other combination 
approaches. One approach is to use inhibitors targeting lesser-studied pro-survival signaling pathways in 
PDAC cells. For example, one such target downstream of Ras in cancer is the p21-activated kinase (PAK) 
family pathway. One member of the PAK family, PAK1, has been shown to be important for BCL-2 
expression, and combining this inhibition with TBK1 could decrease expression of two anti-apoptotic 
proteins, thus inducing apoptosis. 
An alternative approach is to use the Drug Sensitivity and Resistance Testing (DSRT) platform to 
screen for compounds that cooperate or synergize with LSN3090279 [208]. The compounds available for 
testing by DSRT cover multiple drug classes and include chemotherapeutics, kinase inhibitors, and 
immunosuppressants, thus allowing for inhibition of targets that may not be considered in the Ras effector 
pathway approach. 
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Which proteins confer resistance to TBK1 inhibition?  
My studies show that the majority of PDAC cell lines are resistant to TBK1 inhibition in terms of 
proliferation. However, the mechanism of resistance to LSN3090279 has not been explored. To do this, I 
would use two approaches. First, I would perform an siRNA screen against targets that have been 
implicated in the K-Ras signaling network. I would monitor cell viability and determine if the depletion 
of a specific protein in resistant PDAC cell lines sensitizes cells to LSN3090279 treatment. Second, as a 
complementary approach to the siRNA screen, I would use the Cancer Toolkit described previously that 
was used to identify Notch1 activation as a mechanism of acquired resistance to MAPK inhibitors in 
BRAF V600E-mutant melanomas [209]. Briefly, in cell lines identified as sensitive to LSN3090279, I 
would express a barcoded library of cDNAs encoding activated mutants of signaling components of 20 
known cancer pathways. I would then treat cells with the inhibitor and monitor cell viability in order to 
determine which activated components conferred resistance to TBK1 inhibition. 
Conclusion 
 My studies have examined targeting the Ras-Ral signaling pathway in cancer both through loss of 
proteins responsible for Ral association with the plasma membrane and through inhibition of the 
downstream effector TBK1. I found that posttranslational modification of the CAAX motif of Ral 
proteins has differential consequences on their activity, stability, and subcellular localization, and this 
work suggests the impact of these modifications on other CAAX-containing proteins involved in cancer 
signaling should also be addressed. I also confirmed that pharmacologic inhibition of TBK1 has a 
minimal impact on cancer cell proliferation, and found that instead combination with another targeted 
inhibitor may be more effective.  In an era when combination therapies for the treatment of cancer are 
becoming increasingly popular, this finding can inform future studies of how TBK1 inhibitors can be 
implemented most effectively. In conclusion, these studies serve to advance the field of targeting Ral for 
the treatment of cancer. 
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